Podcasts about Remission

Singer-songwriter and Lyme disease advocate Jesse Ruben joins the Tick Boot Camp Podcast for an incredibly honest, emotional, and deeply educational conversation about chronic Lyme disease, identity loss, treatment failure, unconventional healing, relapse, nervous system trauma, and the role of music and community in survival. Jesse's journey spans more than a decade and includes misdiagnosis, years of antibiotic treatment, experimental therapies, remission, relapse during the pandemic, gut microbiome restoration, nervous system healing, and ultimately a renewed sense of purpose through advocacy and art. This episode is essential listening for anyone navigating chronic Lyme disease, supporting someone who is sick, or questioning whether healing is still possible. Jesse Ruben's Early Life and Music Career Jesse grew up outside Philadelphia, surrounded by music, creativity, and curiosity. While he jokes that his songwriting degree was “a very expensive, useless piece of paper,” the competitive creative environment of music school helped sharpen his storytelling voice. By his early 20s, Jesse was living in New York City, touring, running marathons, and building momentum as an independent musician. He had just completed his third New York City Marathon, was in peak physical condition, and his career was accelerating—until his health began to unravel. The Onset of Illness: When Lyme Disease Took Everything Jesse's first red flag appeared when he became short of breath climbing subway stairs, despite being a marathon runner. Soon after, nausea, dizziness, headaches, neurological symptoms, and crushing fatigue followed. On Christmas Day 2012, Jesse developed what seemed like a flu that never went away. Over the following months, symptoms escalated dramatically: Severe fatigue that made basic movement impossible Brain fog and memory loss Crawling sensations under the skin Air hunger and dizziness Anxiety, depression, and mood changes Weight loss and neurological dysfunction Despite seeing 15 doctors over nine months, Jesse received conflicting diagnoses ranging from vitamin deficiencies to fibromyalgia and lupus. Every test came back “normal.” Insurance denied coverage. Doctors told him he would “have to live with it.” During a national tour, Jesse was so debilitated that a friend physically lifted him onto the stage to perform, then carried him back to the van afterward. Eventually, through relentless self-research, Jesse discovered a symptom list online that finally connected the dots: Lyme disease. Diagnosis and Early Treatment Failure Jesse was ultimately diagnosed at the Morrison Center in New York City, where testing confirmed: Lyme disease Babesia Mycoplasma His initial treatment path included: 6 months of oral doxycycline 18 months of IV azithromycin Antiparasitics Mepron (for Babesia) Antifungals, antivirals, supplements, and Chinese herbs Despite years of treatment, nothing produced lasting improvement. Jesse describes his life during this period as being reduced to pill schedules, doctor visits, and survival mode. The Game Changer: Chelation and Ozone Therapy After nearly three years with minimal progress, Jesse's provider, Dr. Gerald (“Jerry”) T. Simons at the Morrison Center, suggested a more experimental approach: chelation combined with ozone therapy. Jesse underwent IV chelation and ozone therapy multiple times per week for several months. The results were dramatic. Nearly all of Jesse's symptoms resolved, and for the first time, he felt like himself again. Even years later, booster ozone treatments helped stop symptom flares before they escalated.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/AAPA information, and to apply for credit, please visit us at PeerView.com/JGX865. CME/MOC/EBAH/AAPA credit will be available until January 4, 2027.Many Roads to Myeloma Remission: Making Sequential Choices With BCMA and Non-BCMA Immunotherapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical educational grants from Arcellx, Inc. and Kite, a Gilead Company; GSK; Johnson & Johnson; and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PWK865. CME/MOC/EBAH/AAPA/IPCE credit will be available until January 4, 2027.Pathways to Personalized Remission in CLL: Leveraging Targeted Standards & Next-Gen Advances for Upfront and Sequential Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, BeOne Medicines, and Lilly.Disclosure information is available at the beginning of the video presentation.

The only symptom that 14 year old Adie Alonzo was showing beginning in the spring of 2024 was an enlarged lymph node on her left side that had not impacted Adie's health in any way. It was not until 7 months later that this swollen lymph node was diagnosed as Hodgkins Lymphoma. After undergoing difficult treatment at Kaiser Hospital in Fontana California, Adie achieved remission on May 29th of 2025 and is doing well as 2026 begins. Adie is now 16 years old. 

In this real Q&A, I answer questions from someone newly diagnosed with RA who's currently taking hydroxychloroquine (Plaquenil). We talk through what “treat-to-target” actually means, why early control of inflammation matters, and how to think about medication fears in a way that's grounded (not scary).In this video, we cover:--What “treat-to-target” means and why timing is a big deal in RA--Minimal Disease Activity (MDA) vs. “just getting by”--When Plaquenil may not be enough, and what escalation can look like (DMARDs/biologics)--How to weigh medication risks against the risks of untreated RA (including long-term steroid use)--Lifestyle support that helps inflammation (stress, sleep, vagus nerve) — plus why smoking mattersQuestion for you: What's the #1 thing you wish someone explained right after your RA diagnosis?#RheumatoidArthritis #RA #AutoimmuneDisease #Rheumatology #Plaquenil #Hydroxychloroquine #Methotrexate #Biologics #TreatToTarget #JointPain #Inflammation #ChronicIllness

Send us a textDr. Heather Stone is a returning guest on our show! Be sure to check out her first appearance on episode 833 of BBR!Dr. Heather Stone, DC is one of the most successful functional medicine practitioners in the world. She has spent the last twenty-one years helping patients reverse various chronic diseases. Her focus is on helping women return to the person they know themselves to be by experiencing a total thyroid transformation. She is passionate about health, longevity, gardening, cooking, regenerative farming, and raising her animals on her ranch.Dr. Heather also currently runs two functional medicine clinics, as well as Born To Heal Ranch & Retreat, which is a functional medicine retreat center for women dealing with hypothyroidism and Hashimoto's.Throughout her career, Dr. Heather has been instrumental in showing tens of thousands of patients how to reverse long-standing health problems with a focus on type 2 diabetes, hypothyroidism, and cognitive decline. She is also the author of her amazing book Thyroid Transformation Blueprint.Dr. Heather is married and has two sons, Cam and Cannon, and currently lives on her ranch in Texas with her family and two dogs. When she is not working, she is reading, meditating, cooking, or traveling the world.Find Dr. Heather at-https://reversemycondition.com/FB Page- Happy, Healthy and Lean- Women Overcoming Low Thyroid!IG- @drheatherstonehttps://www.borntohealranchandretreat.com/Find Boundless Body at- myboundlessbody.com Book a session with us here!

David Jernigan 0:15Hello! Dr. Deb 0:16Hi there, sorry for all the confusion. David Jernigan 0:19Oh, no worries, you gotta love it, right? Dr. Deb 0:21Oh, I can’t hear you. David Jernigan 0:23No way, let’s see, my mic must be turned off? Dr. Deb 0:27Hang on, I think it’s me. Let’s see…Okay, let’s try now. David Jernigan 0:40Okay, can you hear me? Dr. Deb 0:42Yep, I can hear you now. David Jernigan 0:43Excellent, excellent. And, how are you today? Dr. Deb 0:48I am good, thank you. How about yourself? David Jernigan 0:50I’m good. Well, it’s good to finally meet you and get this thing rolling. Dr. Deb 0:56Yes, yes, I’m so sorry about that. David Jernigan 0:58That’s alright, that’s alright.So… Dr. Deb 1:01Yeah, go ahead. David Jernigan 1:03So, tell me about yourself before we get going. Dr. Deb 1:06Yeah, so I am a nurse practitioner. I’m also a naturopath. I have a practice here in Wisconsin. I’ve been treating Lyme for about 20 years, so I’m really excited to have this conversation and learn what you’re doing, because it’s so exciting and new. David Jernigan 1:21Well, thank you. Dr. Deb 1:22Yeah, so we treat a lot of chronic illness patients, do some anti-aging regenerative things as well, so… David Jernigan 1:30Yeah, I went to your website and saw you guys are killing it, looks like. Dr. Deb 1:35Yeah. David Jernigan 1:35Got a lot of good staff, it looks like. Dr. Deb 1:37Yeah, we’ve got great staff, great patients, busy practice. We have 5 practitioners, so we have about 15,000 patients in our practice right now. David Jernigan 1:46Well, excellent. Yeah. Excellent. Yeah, yeah.So, I’m excited for this discussion. Dr. Deb 1:53Good, me too. So I pre-recorded our intro, so we can just kind of dive right in, and I’ll just ask you to kind of introduce yourself a little bit, tell us a little bit about yourself, and, and then we can just dive right into it. David Jernigan 2:08All right. I’m Dr. David Jernigan, and I own the Biologic Center for Optimum Health in… Franklin, Tennessee, and I’ve been in practice for over 30 years. I shook Willie Bergdurfer’s hand, if anybody knows who that is. It’s kind of infamous now with some of the revelations that have happened about Lyme being a bioweapon and weaponized. But, you know, I’ve been doing this, probably longer than almost anybody that’s still in the business in the natural realm. It chose me. I did not choose Lyme. Matter of fact, there were many times in my career that I was like. You know, cancer’s easier because of the fact that everybody agrees, you know, what we’re dealing with. And in the 90s, it was a whole different reality, where nobody actually understood that you could have Lyme disease and not be coming from New England.You know, so I had actually the first documented case of a Lyme disease, CDC positive.Patient that had never left the state of Kansas before. So they couldn’t say that it wasn’t in Kansas, and so she had actually been, pregnant with… twin boys, and they were born CDC-positive as well, and so it is transmitted across the placenta we know.So, I, you know, the history of how I did all this was, in the 90s, probably 1996, probably, somewhere in there, 97. With this woman, you know, I… if you go into Robin’s pathology books from back then. Which we all used, medical doctors and everybody else studying. you know, there was basically a paragraph about Lyme disease, and on the national board tests, as you recall, it was probably like, what causes, or what is, bullseye rash associated with? And you’d had to guess Lyme disease, of course. Dr. Deb 4:07Female. David Jernigan 4:08But that was, you know, considered to be more a New England illness, and you would never see it anywhere else. But here was this woman. I knew… nothing about Lyme beyond what we had gotten taught in college, which was, like I say, next to nothing. And she would not let me stop feeding me information. I mean, you gotta remember, the internet wasn’t even hardly in existence in those years. I mean, it was brand new. It was supposed to be this information highway, and So I started purchasing, like a lot of doctors do even now, they start purchasing every kind of new supplement that’s supposed to work for bacteria. There was no product in those days that actually was Lyme-specific. I mean, nobody was really dealing with it naturally. It was always a pharmaceutical situation. Dr. Deb 5:04And a very short course at that. David Jernigan 5:06Yeah, 2 weeks of doxy and you’re cured, whether your symptoms are gone or not, which… she’d had the 2 weeks of doxy, and her symptoms and her son’s symptoms were not gone. And so, I absolutely just purchased everything I could find. Nothing would work. I mean, I could name names of products, and you would recognize them, because they’re still out there today. Dr. Deb 5:28Which is. David Jernigan 5:30Kind of a… A sad thing that natural medicine is still riding on these things that have the most marketing. Dr. Deb 5:37As opposed to sometimes the things that actually have the documented research. David Jernigan 5:42Behind it, and I am a doctor of chiropractic medicine, and I specialized all these years in chronic, incurable illnesses of all types. That may sound odd to a lot of people, but doctors of chiropractic medicine are trained just like a GP typically would be. The medical schools, as I understand it, got together, decades ago and said, wow, if all we did was… Crank out general practitioners for the next 10 years, we wouldn’t have still enough general practitioners to supply the demand. Dr. Deb 6:17Right. Everybody in medicine, in medical schools, wanted to be a specialist, because that’s where the money was, and it was… David Jernigan 6:24Easier, kind of, also, to… you know, just focus on one part of the body, and specialize in that. Dr. Deb 6:31Expert in that one area. David Jernigan 6:32So we all now have the same training. We all go through pre-med. We got a bachelor’s degree, I got my bachelor’s degree in nutrition, and through, Park University in Parkville, Missouri. And so, you know, when I ran out of options to purchase, I just used a technology that I developed, which was an advancement upon other technologies, but I called it bioresonance scanning. And I coined the term back in the 90s. It was a way to kind ofKind of like a sensitive test, you know, like you might. Dr. Deb 7:09I wouldn’t. David Jernigan 7:09Of applied kinesiology, then clinical kinesiology, then chiro plus kinesiology, then, you know, you can just keep going with all the advancements that were made. Well, this was an advancement upon those things, so… I developed… I was the first in… in… my known world of doctors to develop a way to detect adjunctively, obviously we can’t say it’s a primary diagnosis. Adjunctively detect the presence of a given specimen. So we could say, thus saith my test. It’s highly likely you have Borrelia burgdurferi. And, but I had to have the specimen on hand to be able to match what I call frequency matching to the specimen. Brand new concept in those days. And so I was able to detect whether or not my treatments were successful or not. This is something even now that’s really difficult for doctors, because antibody tests, even the most advanced ones, it’s still an antibody test. It’s still an immune response to an infection.And accurately, you know, some doctors will slam those tests, saying, well. That doesn’t mean you actually have the infection, that just means your body has seen it before, which is a correct statement, kind of. So being able to detect the presence, and even where in the body these infections are was a way huge advancement in the 90s, for sure it’s kind of funny, I think about a conference I went to, and cuz… I’m kind of jumping ahead. Because I ended up developing my own formula, just for this woman and her children, and it worked. And I was like, wow! Their symptoms were gone, all the blood tests came back negative. In those days, we were using the iGenX. Western blot, eventually. And the, what was called a Lyme urine antigen test. I don’t know if you remember that, because it… Only decades later did I meet, the owner of iGenX, Nick Harris. Dr. Deb 9:17Person. And I was like, whatever happened to the Luwat test? Because I took it off the market after a while. He said, honestly, we lost the antigen and couldn’t find it again. Oh, no. David Jernigan 9:27And so… but that was a brilliant test. It was the actual gold standard in those days. Again, the world… it can’t be understated how different the world was in the 90s. Dr. Deb 9:40Yeah. David Jernigan 9:41Towards natural medicine, even. Dr. Deb 9:44Oh, yeah. We think… we think it’s bad now, but, like, when I started, too, I started in the early 2000s, like, we were all hiding under the radar, like, you didn’t market, we would have never been on social media, we didn’t run ads, we didn’t do any. David Jernigan 10:00Right. Dr. Deb 10:01Because the medical boards were coming for us. David Jernigan 10:04Came after me. Dr. Deb 10:05Because I had the word Lime on my page, my website. David Jernigan 10:10You know, not saying that I treat Lyme. Dr. Deb 10:13Hmm? David Jernigan 10:13Yes Dr. Deb 10:15Just talking about mind. David Jernigan 10:16And it’s funny, because, once I had this formula, it was something… and I trained in Germany, in anthroposophical medicine, and they’ve been trained in herbal… making herbal extracts, making homeopathic remedies in the anthroposophical methodology, and I trained with the Hahnemann versions of homeopathy, which is just slightly different. Yeah. And, so I was well-versed with making some of my own formulas by that time. And so, it was really something that I wrote on the bottle, you know, and I had to call it something, so I called it Borreligin, which is still in existence, and it’s still a phenomenal herbal remedy right now. And to my knowledge, it’s the only frequency-matched herbal formula. Maybe still out there. Because unless you knew how to do my testing, the bioresonent scanning, there was no way to actually do frequency matching. Matter of fact, as a really famous herbalist attacked me online, saying, oh, none of these herbs will kill anything. And I’m like, that wasn’t what I was saying. I was saying, back in those days, I was saying, well, if… what would the body need to address these infections?You know, not, like, what’s gonna kill the infections for the body. Dr. Deb 11:38Right. David Jernigan 11:39Right? So it was a phenomenal way, but the LUAT test was amazing because what you’d do is you would give your treatment, like an MD would give an antibiotic for a week, ahead of time. Trying to increase the number of dead spirochetes showing up in your urine one day out of 3 days urine catch. So you’d wake up in the morning, you’d collect your urine 3 days in a row, and any one of those being positive is a positive. But it was a brilliant test because it wasn’t an antibody test. They were literally counting the number of dead pieces of Lyme bacteria in your urine. I mean, it was pretty irrefutable. So I had a grand slam on the… the Western blot on patients, and I’d also have a grand slam on the LUAT, and their medical doctors would say, oh, that doctor in the lab are probably in cahoots change some lab. Dr. Deb 12:38Of course. David Jernigan 12:39That come in. And I still see that today. You know, it’s like, oh my gosh, the better the tests are getting. There’s still a bias if you do your own research. Well, if you happen to be a doctor who loves research. And you’re a clinician, so you actually treat patients who’s gonna write the research study? Well, of course, the doctor who did the study, well, he’s biased, and I’m like, I still can’t influence lab tests. Well, lab tests aren’t everything. People scream over the internet at me. It’s like, well, a negative lab test doesn’t mean anything. I was like… I get that with the old Western blot testing. Dr. Deb 13:16Right. David Jernigan 13:16The more sensitive tests, which are very close to 100%, Sensitivity, and 100% specificity. So, meaning, like, they can… if you have the infection, they’re gonna find it. Dr. Deb 13:30They’ll find it, yeah. David Jernigan 13:31And if they… if you have the infection, they’re going to be able to tell you exactly 100% correctly what kind of infection it is. Back in those days, you couldn’t, you could just count the dead pieces, which was… Dr. Deb 13:43Yeah. David Jernigan 13:43Significant, but It’s funny, because when medicine does that, you know, mainstream medicine that’s backed by all the nice foundations who donate millions of dollars towards the research. Their negative tests are significant, but if you fund your own, Yours isn’t that significant. Dr. Deb 14:04Right, or what if we call something a seronegative autoimmune disease, like lupus or rheumatoid arthritis, because none of the tests are positive, but you have all the symptoms. Here, let me give you this $100,000 a year drug. David Jernigan 14:19Yeah. Dr. Deb 14:19And instead of looking for what might actually be causing the symptoms. That’s all okay, but what we do is not okay. David Jernigan 14:27Right. Yeah, it’s a double standard, and it’s getting better. I want to do… tell the world it is getting better. Some of the dinosaurs are retiring. Dr. Deb 14:36No. David Jernigan 14:37Way for people who are… Are more open-minded to new ideas. But, getting back to that woman, she… that formula that I made just for her and her son, I… She went online. Dr. Deb 14:54Which, I had never been on a news group. David Jernigan 14:58Not even sure I knew what one was, you know? Imagine, I’m kind of that dinosaur that… Cell phones were, like, these really big things with a big antenna sticking out of it, and… Dr. Deb 15:09Nope. David Jernigan 15:10So I thought I was pretty hot stuff, just that I actually had a computer software program that was running my front desk. And even then, it was an Apple IIe computer. Dr. Deb 15:21Right. David Jernigan 15:22Probably be pretty valuable right now if I’d kept it, but… Dr. Deb 15:25Mmm… David Jernigan 15:26It being an antique. But, suddenly people were calling my clinic, because the lady with the twin boys that was well was telling people on these research, I mean, these Lyme disease forums and boards online. And, I started going, oh my gosh, you know, as a doctor, it’s one thing to treat a person in your clinic, it’s a different thing to have your clinic name on the label. Like, we all do, Even now, and you’re supposed to write everything that’s on the label, and… all these guidelines, and I’m like, wow, I need to split this off. I mean, I def… I definitely want to help people, and this is… I was pretty excited about the results we were getting. Pre-treat… Pre-treatment and post-treatment. And, so… that’s where I developed, my nutraceutical business in the 90s called Journey Good Nutraceuticals. My advice to anybody thinking about doing the same thing, don’t put your last name on it. Dr. Deb 16:25– David Jernigan 16:25You know, because anytime negative anything comes out, there goes the Jernigan name, you know, the herbal, you know, there’s just all these, and especially nowadays, with all the bots that are just designed to slam natural medicine. Dr. Deb 16:38Yeah. David Jernigan 16:39And that is out there in a… and just ugly people. Dr. Deb 16:42Or should we just say, people with a different opinion? How’s that? David Jernigan 16:46Yeah. That are being less than supportive. Dr. Deb 16:49But. David Jernigan 16:51It was amazing, because by 1999, I presented my research, my first research, I’d never done research. This is what I would… I would say to a lot of people who go, my doctor did… I don’t know, my doctor doesn’t know what you’re doing, my doctor… I was like going, you know, most doctors don’t do research. They don’t publish anything. Their opinion is their opinion, but they don’t back it up in peer review, right? And so that’s what I always tried to do, was back it up in peer review and publish. And so, in 1999, I presented at the International Tick-Borne Diseases Conference in New York City. I’m telling you, it was like the country boy going to the city, you know, I got my… I got my suit on, and I looked all right, and my booth was wonderful, and all these different things, and it was just a big wake-up call.Because what we had demonstrated… let’s get back to the… and this was what I demonstrated with that first study. was that… A positive LUAC test, that Lyme urine antigen test for my Gen X, was a score of 32. Meaning, one of those 3 mornings urine had 32 pieces in the amount of urine they checked of deadline bacteria spirochetes. Okay? Okay. With antibiotic challenges, a highly positive was a score of 45. Dr. Deb 18:19Wow when I would give one dropper 3 times a day for a week. David Jernigan 18:24Ahead of time, and then do the person’s LUAT test, We were getting scores 100, 200… And at that point, we only had a couple, but we had a couple that were greater than 400. Yeah, dead pieces, where the lab just quits counting. They just said, somewhere over 400, right? Dr. Deb 18:45Yeah. David Jernigan 18:46Which, when the medical system at the conference, you know, I was the only natural doctor in the world that was… had any kind of proof of anything naturally that could outperform antibiotics. Can you imagine? Dr. Deb 18:59Yeah. And… David Jernigan 19:01They were just, oh my gosh, incredulous. They’re like, I’ve given the most… one guy came up to me, and to my face, and he goes, I’ve given the most aggressive antibiotic protocols And I’ve only seen one patient over 100. I was like, that makes this pretty significant, doesn’t it? But, it didn’t just, like, make us take off, because guess what? In Lyme world, if a pharmaceutical antibiotic made you feel horrible. That meant it was working. Dr. Deb 19:28That’s right. We used to, back in the day, if you didn’t herx. And had that horrible die-off reaction, for those of you who don’t know what a herx is, but if we didn’t make you herx, we weren’t doing our job right. David Jernigan 19:40You’re looking for your patients to feel horrible, and sometimes to the level of committing suicide. Dr. Deb 19:46Yes. David Jernigan 19:47So bad. Dr. Deb 19:48Yes. David Jernigan 19:49And I was the first doctor, I think, in the world to start screaming and hollering and saying, stop using the worsening of your patient’s symptoms as a guide to good treatment, because they’re… I wasn’t seeing it with my formulas. Because I was doing a comprehensive program of care. I think I was also one of the first doctors to say, we need to detoxify these people as we’re doing this. And you would sit there and say, well, sure you were. I was like, well, remember, there wasn’t a lot of communication. There wasn’t anybody on the internet saying, do this, do that. And, It was, it was interesting in those days. It was, how do you… How do you help the world heal from these things? That they don’t know they have. So later, I actually had a beautiful booth at a health… a big health expo in Texas, I remember, and I was like, you know, you spend a lot of money on the booth, and… Dr. Deb 20:43Yup. David Jernigan 20:43And you’re thinking about it because you’re funding the whole thing, you say, wow, if I only sell one case, I’ll at least cover my cost. Dr. Deb 20:51Yep. Yeah, you’re great. David Jernigan 20:52And I had this beautiful banner of, like, a blown-up tick’s mouth under microscope. You know those beautiful pictures of, like, all the barbs sticking out, and how they anchor themselves in your skin, and… And, thousand people walking by my booth, and they’re just like, keep walking, because they didn’t know they had Lyme. There was, like, and they had MS, maybe, but they don’t have Lyme, and so they just would keep walking. Nobody even knew. Why would I go to a conference in Texas? And I’m trying to say, no, guys, it’s everywhere. Dr. Deb 21:24Yeah. David Jernigan 21:24And… and everybody, you know, yes, you probably have this, you know, kind of thing. If you’re… if you… are chronically ill, almost, of any kind of way. You know, kind of trying to tell people this was… Again, in Robin’s pathology textbooks, one of the few things that it did tell you about Lyme was that it was called the Great… the New Great Imitator. Because it would imitate up to 200 or more different illnesses. So, it’s been an interesting journey, of… educating people, writing articles, but it was interesting, the lady who I first fixed, Laboratory verified, everything like that, symptoms went away, all that kind of fun stuff. Her children were fine, they’ve been fine for years now. When she went on the newsboards in the Lyme disease support groups, It created a war. Oh my goodness, it was like, how dare you? And, say that something natural might actually help, right? Dr. Deb 22:30Right, exactly. David Jernigan 22:32And, I even had… A… one of those first calls to… with a marketing company at one point, way a long time ago. And the lady got on the phone, the owner of the marketing company goes, I would have blood on my hands if I actually took your clinic on. Yeah, you can’t treat Lyme disease, and… Even the big, big associations that are out there are still largely that way. I mean, they’re getting better, but it’s just like… you know, a lot of the times, it’s herbs are good. Herbs will help. Good, you know, but they’re safe. So, it’s still a challenge to… to… present in mainstream Lyme communities, even. Because there’s this… Fear of doing anything outside of antibiotics. Dr. Deb 23:32Yeah, so let me ask you this. From your perspective. Why do you think so many chronic infections exist these days, like Lyme and the co-infections, Babesia, Bartonella, mold illness? And we talked a little bit about herbs and why they, antibiotics and things like that fail, but let’s talk a little bit about that. David Jernigan 23:53So, it’s fascinating. When I trained in Germany, they said that we, as humanity, has moved away from what they called the inflammatory diseases. You know, in the old days, it was. Lots of high fevers, purulent, pus-generating bacterial infections. And I said, as a society, we have… Dr. Deb 24:14Have shifted from those to what they call cold sclerotic diseases, which are your… David Jernigan 24:21Cancers, your diabetes, your atherosclerosis, your… and they said, we’re starting to see what used to only be geriatric diseases in our children. That’s how bad it’s gotten. We have suppressed fevers, we don’t… we don’t respect the wisdom of the human body. So, you know, the doctors say, step aside, body, I will fix this infection for you with this antibiotic. And so, what we’ve done with the, overuse of antibiotics, and this isn’t me just talking from a natural perspective, this is… Right, it’s everybody around the world is acknowledging. I’ll show you… I could show you a, a presentation, if we can do a screen-sharing situation. Yeah. About the antibiotic situation in the world, because it’s really concerning. But what I would say, and kind of like an advancement forward, is we are seeing mutated bacteria. You know, they talked about… do you remember when they found the Iceman, you know, the… You know, the prehistoric guy that’s… In the eyes, and he had Lyme bacteria. I was like, he had spirochetes, maybe. Dr. Deb 25:33Yeah. David Jernigan 25:33That isn’t a modified, mutated version. That’s just maybe the… Lyme… you know, Borrelia… call it Borrelia something, you know, it’s a spirochete, but what we’re dealing with today. Even under strep or staph, as you know, you know, Pseudomonas aeruginosa, you name it, whatever kind of infection a person has is not the same bacteria that your grandparents dealt with. Dr. Deb 26:01That’s right. David Jernigan 26:32It’s a much mutated, stronger, more resistant to treatment type of thing. So, I think that’s one reason. I think the, It’s great that we’re seeing, you know, Secretary Robert F. Kennedy Jr. bringing awareness to things that Like it or not, yeah, seed oils do create inflammation, and everyone in the natural realm, as you know. Has been trying to say this for probably how long? Dr. Deb 26:35Yeah, 25, 30 years. 20 years each. David Jernigan 26:48Yes. You know, thank goodness for people like Sally Fallon and her beautiful book, Nourishing Traditions, that started you know, Dr. Bernard Jensen’s books way back in the day, Dr. Christopher’s books way back in the day. Dr. Deb 26:48Damn. David Jernigan 26:49You know, all of them were way ahead of their time, saying, by the way, your margarine is only missing one ingredient from being axle grease. Dr. Deb 26:58Yeah. David Jernigan 26:58I think that was Dr. Jensen saying that at one point, probably 50, 60 years ago, I don’t know. Dr. Deb 27:03Yep. David Jernigan 27:04So, we’ve created this monster. We, we live in a very controlled environment, you know, of 72, 74 degrees at all times, we don’t sweat, we don’t have to work that hard, typically. You know, most of us aren’t out there like our ancestors were, so that’s making us more and more… Move towards the cold sclerotic diseases, of which even Lyme disease is, you know, which… Yes, it has inflammation, yes, but as a presentation, it’s very often associated with some of these Cold sclerotic diseases of mankind that we see now. Dr. Deb 27:46You have it. David Jernigan 27:47Yeah. Dr. Deb 27:48So, tell me, what is phage therapy? David Jernigan 27:52Well, may I show you a cool video? Dr. Deb 27:55Yeah, I’d love that. David Jernigan 27:56I did not make this video, this is just one of my favorites, because it’s from the National Institute of Health. Let’s see if I can just… Click the share screen thing. And get that to pop up. That’s not what I’m looking for, but it’s gonna be soon. Let’s go here… Alright, can you see that? Dr. Deb 28:18Yeah. David Jernigan 28:19Okay. Modern medicine faces a serious problem. Thanks in part to overuse and misuse of antibiotics, many bacteria are gaining resistance to our most common cures. Researchers are probing possible alternatives to antibiotics, including phages. So, bacteriophages, or we like to call them phages for short, are naturally occurring viruses that infect and kill bacteria. The basic structure consists of a head, a sheath, and tail fibers. The tail fibers are what mediate attachment to the bacterial cell. The DNA stored in the head will then travel down the sheath and be injected inside the cell. Once inside the cell, the phage will hijack the cellular machinery to make many copies of itself. Lastly, the newly assembled phages burst forth from the bacterium, which resets their phage life cycle and kills the bacterium in the process. Someday, healthcare providers may be able to treat MRSA and other stubborn bacterial infections using a mixture of phages, or a phage cocktail process would be first to identify what the pathogen is that’s causing the infection. So the bacterium is isolated and is characterized. And then there’s a need to select a phage in a process known as screening of phage that are either present in a repository or in a so-called phage library. That allows for many of the phages to be evaluated for effectiveness against that isolated I don’t know, bacterium. Phages were first discovered over 100 years ago by a French-Canadian named Felice Derrell. They initially gained popularity in Eastern Europe, however, Western countries largely abandoned phages in favor of antibiotics, which were better understood and easier to produce in large quantities. Now, with bacteria like these gaining resistance to antibiotics, phage research is gaining momentum in the United States once again. NIAID recently partnered with other government agencies to host a phage workshop, where researchers from NIH, FTA, the commercial sector, and academia gathered to discuss recent progress. NIH… So… That is… That is what phage therapy in… is. in what I call conventional phage. Let’s see, how do I get out of the share screen? Hope you already don’t see it. Dr. Deb 30:58Yep, at the top, there should just be a button. David Jernigan 31:00I don’t. Dr. Deb 31:00Stop sharing, yeah. David Jernigan 31:01So… Conventional phage therapy, as you just saw, is a lot like what it is that we’re doing, only the difference is they’re taking wild phages from the environment. They’re finding phages anywhere there’s, like, a lot of bacteria. And then they isolate those phages, and like he said, the gentleman at the very end said we put them in a library, and so there are banks of phages that they can actually now use, and One of the largest banks that I know of has about 700 different bacteriophages, or phages. In their bank that they can pull from. Dr. Deb 31:43Wow. Do you want to take a guess? David Jernigan 31:46How many bacteriophages they’ve identified are in the human gut, on average? Dr. Deb 31:52Oh my god, there’s gotta be more… David Jernigan 31:53Kinds, different kinds of phages, how many? Dr. Deb 31:56There’s gotta be millions. David Jernigan 31:57Well… In population, there’s… humongous numbers, numbers probably well beyond the trillions, okay? Hundreds of trillions, quadrillions, maybe, even. But in the gut, a recent peer-reviewed journal article said that there were 32,242 different types of bacteriophages that live naturally in your intestines, your gut. Dr. Deb 32:25Boom. David Jernigan 32:2632,000. Okay, so… If you read any article on phage therapy that’s in peer review, almost every single one in the very first paragraph, they use the same sentence. They go, Phages are ubiquitous in nature. They’re ubiquitous in nature. So my brain, when I find… when all this finally clicked together, and when we clicked together 5 years into my research, I could not get it to work for 5 years. I just kept going. But that sentence really got me going. I was, like, going, you know. If you look at what ubiquitous means, it says if Phages were the size of grains of sand. Like sand on the beach. They would completely cover the earth and be 50 miles deep. How crazy is that? Dr. Deb 33:24Wow. David Jernigan 33:25That’s how many phages are on the planet. There’s so many… they outnumber every species collectively on the planet. So, it’s an impossibility in my mind. I went, huh, it’s an impossibility that… You catching a, a sterile Bacteria, it’s almost an impossibility. Since the beginning of time, phages have been needing to use a reproductive host. And it’s very specific, so every kind of bacteria has its own kind of phage it uses as a reproductive host. Because phages are… and this is a clarification I want to make for people. just like in the old days, we were talking about the 90s, I talked to a veterinarian that had gotten in trouble with the veterinary board in her state. Dr. Deb 34:14Back in the old days. David Jernigan 34:16Because she gave dogs probiotics. And the board thought she was giving the dogs an infection so that she could treat them and make money off of the subsequent infection. Dr. Deb 34:28Oh my god. David Jernigan 34:29Nobody actually had heard of good, friendly bacteria in the veterinary world, I guess she said she had gotten in trouble, and she had to defend herself, that, no, I’m giving friendly, benevolent, beneficial bacteria. Okay, to these animals, and getting good results.So, phages… Are friendly, benevolent, beneficial viruses. That live in your body, but they only will infect a certain type of bacteria. So… What that means is if you have staff.Aureus, you know, Staphylococcus aureus bacteria. That bacteria has its own kind of phage that infects it called a staph aureus phage. E. coli has an E. coli phage. Each type of E. coli has its own phage, so Borrelia burgdurferi has its own Borrelia burgdurferi type of phage, whereas Borrelia miyamotoi alright? Or any of the other Borrelia species, or the Bartonella species, or the… you just keep going, and Moses has its own type of phage that only will infect that type of bacteria. So that’s… You know, when you realize, wow, why are we going to the environment Was my thought. Dr. Deb 35:54Yeah. David Jernigan 34:55Trying to find wild phages and put them into your body, and hopefully they go and do what you want them to do. What if we could trigger the phages themselves that live in your body to, instead of just farming that bacteria that it uses as a host, because what I mean by farming is the phages will only kill 40% of that population of bacteria a day. Dr. Deb 36:20Wow. David Jernigan 36:20And then they send out a signal to all the other phages saying, stop killing! Dr. Deb 36:24It’s like. David Jernigan 36:2560% of the bacteria population left to be breeding stock. It’s kind of like the farmer, the rancher, who… he doesn’t send his whole herd to the butcher. Dr. Deb 36:35Right. David Jernigan 36:36Just to, you know, he keeps his breeding stock. He sends the rest, right? So, the phages will kill 40% of the population every day, just in their reproduction process. Because once there’s so many, as you saw in the video, once the phage lands on top of the bacteria, injects its genetic material into the bacteria, that bacteria genetic engine starts cranking out up to 5,200 phages per bacteria. Dr. Deb 37:06I don’t know who counted all those… David Jernigan 37:08Inside of a bacteria, but some scientists peer-reviewed it and put it out there. that ruptures, and it literally looks like a grenade goes off inside of the bacteria. I wish I’d remembered to bring that video of a phage killing a bacteria, but it just goes, oof. And it’s just a cloud of dust. So, you’re breaking apart a lot of those different toxins and things. So… That’s… That was the impetus to me creating what I did. That and the fact that I looked it up, and I found out that phages will sometimes go… Crazy. I don’t know how to say it. Wiping out 100% of their host. And it could be a trigger, like change in the body’s pH levels, it could be electromagnetically done, you know, like, there’s been documentation of… I think it was, 50 Hz, electricity. Triggering one kind of phage to go… Crazy and annihilate its host population. There’s other ways, but I was, like, going, none of those fit me, you know? It’s not like I’m gonna shock somebody with a… Jumper cable or something to try to get phages to… to do that kind of thing. But the fact that it could be done, they can be triggered, they can switch and suddenly go crazy against their population. But what happens when they kill 100% of their host? The phages themselves die within 4 days. Dr. Deb 38:45Hmm. Because they can’t keep reproducing. David Jernigan 38:47There’s nothing to reproduce them, yeah. Dr. Deb 38:49Yeah. Especially… unless they’re a polyvalent phage, that means a phage that can segue and use. David Jernigan 38:54One or two other kinds of bacteria. To, as a reproductive host. But a lot of phages, if not the majority, are monovalent, which means they have one host that they like to use. And so… Borrelia, so… my study that I ended up doing, and I published the results in 2021, And it’s a small study, but it’s right in there at the high end, believe it or not, of phage research. Most phage research is less than 30 people. In the study. But, we did 26 people.And after one month of doing the phage induction that I invented, which only… Appears to only, induce or stimulate the types of phages that will do the job in your body. I don’t care what kind of phage it is. I don’t care if it’s a Borrelia phage, it may be a polyvalent phage that normally doesn’t use the Borrelia burgdurferi as its number one. Host, but it can. To go and kill that infection. And the fascinating thing is, there was a brand new test that came out at the same time I came out with the idea, literally the same weekend they presented. Dr. Deb 40:1511. David Jernigan 40:15ILADS conference in Boston in 2019. It was called the Felix Borrelia phage Test. So the Felix Borrelia phage test. Because Borrelia are often intracellular, right, they’re buried down in the tissue, they’re not often in the blood that much. And therefore, doing a blood test isn’t really that accurate. But you remember how there’s, like, potentially as many as 5,200 phages of that type erupt from each bacteria when it breaks apart. It’s way easier to detect those phages, because they’re now circulating, those 52, as you saw in the video. 5,200 different phages are now seeking out another Borrelia that they can infect. And so, while they’re out in circulation, that’s easy to find in the bloodstream. So, 77% of the people, so 20 out of 26, were tested after a 2-week period. After only a 4-day round of treatment. Because according to my testing, remember, I can actually test adjunctively to see if I can find any signatures for those kinds of bacteria. And I couldn’t after 4 days, so we discontinued treatment and waited Beyond the 4 days that would allow the phages themselves to die, so we waited about a week and a half.And redid the test. And 77%, so that 20 out of 26 of the people, were completely negative. Dr. Deb 41:50Wow. David Jernigan 41:52Which, you go, well, it’s just a blood test. Well, no, we actually had people that were getting better, like, they’d never gotten better before. We had one woman who was wheelchair-bound, and in two weeks was able to walk, and even ultimately wanted to work for my clinic. I’m just, like, going… Dr. Deb 42:07I didn’t want to write about all that. I wanted to write about the phages. I was like… David Jernigan 42:12article, I probably should have put some of those stories, because, Critics would say, well, you got rid of the infection, maybe, but… Did you fix the Lyme disease? Well, that’s… there’s two factors here that every doctor needs to understand. There’s the infection in chronic illness, there’s the infection, and then there’s the damage that’s been done. Because sometimes I have these people that would come in and say, well, Dr. Jernigan, it didn’t work for me, I’m still in the wheelchair. And I’m like, no, it worked. Repeat lab test over months says it’s gone, it’s gone, it’s gone. It’s like, we would follow, and 88% of the people we followed long-term were still negative, which is amazing to me. Dr. Deb 42:56And then they have to repair the damage. David Jernigan 42:59It’s the damages why you still have your symptoms. And that’s where the doctor has to get busy, right? Dr. Deb 43:06Right David Jernigan 43:06They were told erroneously by their doctor that originally treated them that they’d be well, they’d get out of the wheelchair, if he could actually kill all these infections. Dr. Deb 43:15It’s not true. David Jernigan 43:16Unless it’s caught early. So I love the analogy, and I’ve said it a thousand times.that Lyme disease and chronic infections are much like having termites in the wood of your house. If you find the termites early, then yeah, killing the infection, life goes back to normal, the storm comes and your house doesn’t fall down. But if it’s 20 years later. Killing the termites is still a grand idea. Right. But you have the damage in the wood that needs to be repaired as well. All the systems… when I talk about damage to the wood, I mean, like. All the bioregulatory aspects of the body, how it regulates itself, all the biochemical pathways, the metabolic pathways we all know about, getting the toxins that have been lodged in there for many years, stopping the inflammatory things that have been running crazy. Dealing with all those cytokines that are just running rampant through the body, creating this whole MCAS situation. Which are largely… Dr. Deb 44:21Coming from your body’s own immune cells called macrophages, which are not even… David Jernigan 44:26It’s not… a virus at all, it’s part of the immune system, it’s like a Pac-Man, and research shows that especially in spirochetes. There is no toxin. Now, I wrote 4 books. I think I wrote the very first book on the natural treatment of people with Lyme disease back in the 90s. Why did I write that? Not because I wanted to be famous, it’s a tiny book, actually, the first one was.I was just trying to help people get out of this idea that you will be well when you kill all the bugs. I was saying, it’s… you need to be doing this. If you can’t come to my clinic, at least do this. Try to find somebody that will do this for you. And that ultimately led to a bigger book.as I kept learning more, and I was like, going, well, okay, now at least do this amount of stuff. And you need to make sure your doctor is handling this, this, this, and this. And so, the third book was, like, 500 and something pages long. And then the fourth book was 500 and something pages long, and now they’re all obsolete with the whole phage thing, because this just rewrites everything. Dr. Deb 45:34Yeah. David Jernigan 45:34It’s pretty fascinating. Dr. Deb 45:37Do you think the war on bugs, mentality created more chronic illness than it solved? David Jernigan 45:44Because of the tools that doctors had to use, yes. We’re a minority, we’re still a minority, you and I. Dr. Deb 45:54Yep. Our doctoring… David Jernigan 45:56Methods I never had, and you’d never… maybe you did, but I’d never had the ability to grab a prescription pad and write out a prescription. I had to figure out, how do I get… and this was… and still my guiding thing, is like, how do I identify, number one, everything that can be found that’s gone wrong in the human body. And what do I need to provide that body? Like, the body is the carpenter. That has to do the repair, has to regenerate, has to do everything, has to get… everything fixed right? We can’t fix anything. If you have a paper cut, there isn’t a doctor on the planet that can make that go away. Dr. Deb 46:38Right. David Jernigan 46:39Of their own power, much less chronic illnesses. So, all the treatments are like the screws, saws, hammers, you know the carpenter must be able to use. So a lot of the time, doctors are just throwing an entire Home Depot on top of the carpenter. In the form of, like, bags of supplements, you know, hundreds of supplements, I’ve seen patients walk in my door with two suitcasefuls. And they were taking 70 bottles, 65 to 70 bottles of supplements, and I’d be just like, wow, your carpenter who’s been working for 24 hours a day, 7 days a week. He’s exhausted. There’s chaos everywhere, you don’t know where to. Dr. Deb 47:22Starting. David Jernigan 47:22He goes, you want me to do what with all this stuff? Dr. Deb 47:25Yep, I’ve seen the same thing. People… thousands, you know, several thousand dollars a month on supplements, and not any better. But they’re afraid to give up their supplements, too, because they don’t want to go backwards, either, and… there’s got to be a better way on both sides, the conventional side and the alternative side, although you and I don’t say it’s alternative, that’s the way medicine should be, but… David Jernigan 47:48Right. Dr. Deb 47:49We have to have a good balance on both sides. David Jernigan 47:52And I will say, too, in defense of doctors using a lot of supplements, I do use a lot of supplements. Dr. Deb 47:57Yeah, I do too. David Jernigan 47:58but I want to synergize what I’m giving the patient so that the carpenter isn’t overwhelmed and can actually get the job done. Like, everything has to work harmoniously together, so it’s not that… It’s not the number of supplements, and why would you need a lot of supplements? Well, because every system in your body is Messed up. My kind of clientele for 30 years. Our clientele, yours and mine. Dr. Deb 48:25Yeah. David Jernigan 48:26They have been sick, For decades, many of them. Dr. Deb 48:31Yeah. David Jernigan 48:31And if they went into a hospital, they honestly need every department. They need endocrinology, they need their kidney doctor, they need their… They’re a cardiologists, they need a neurologist, they need a rheumatologist. I mean, because none of those doctors are gonna deal with everything. They’re just gonna deal with one piece of the puzzle. And if they did get the benefit of all the different departments they need, yeah, they’d go out with a garbage bag full of stuff, too. Dr. Deb 48:57Hey, wood. David Jernigan 48:58Only, they’re not synergized. They don’t work together. You’re creating this chemistry set of who knows how much poison. And I want to tell your listeners, and I mean, you probably say this to your patients as well. There is a law of pharmacy that I learned eons ago, and it applies to natural medicine, too. Dr. Deb 49:21Yep. David Jernigan 49:22But the law says every drug’s primary side effect Is its primary action. So, if you listen to TV, you can see this on commercials. I love… I love listening to these commercials, because I’m like, wow. let’s… let’s… I don’t want to say I’ve named Brandon. I don’t know if that’s…Inappropriate to name a name brand, but let’s just say you have a pharmaceutical that is for sleep. After they show you this beautiful scene of the person restfully sleeping and everything like that, they tell you the truth. It’s like, this may cause sleepiness… I mean, sleeplessness. Dr. Deb 50:04Yeah. David Jernigan 50:04Found insomnia. Dr. Deb 50:06And headaches, and diarrhea. David Jernigan 50:08All the other things, and if it’s an antidepressant, what does the commercial do after it finishes showing you little bunny foo-foo, jumping through a green, happy people? They tell you, this may create depression, severe depression, and suicidal tendencies, which is the ultimate depression. So, I want everyone to understand you need to figure out what your doctor’s tools are that they’re asking you to take, and they’re wanting you to take it forever, generally in mainstream medicine, right? In the hospitals and everything. They don’t say, hey, your heart has this condition, take this medicine for 3 months, after which time you can get off. Dr. Deb 50:48Yep. David Jernigan 50:49not fixing it, right? So… That, on a timeline, there is a point, if it was truly even fixing anything. That you… it’s done what it should do, and you should get off, even if it’s a natural product. It’s just like. Dr. Deb 51:03Right David Jernigan 51:03It’s done what it should do, and you should get off, but instead. you go through the tree… the correction and out the other side, and that’s where it starts manifesting a lot of the same problems that it had. So, anti-inflammatories, painkillers, imagine the number one side effects are pain inflammation. So, the doctor says, well. If you say, hey, I’m having more pain, what does he do? He ups the dosage. And if he… if that doesn’t work, if you’re still in a lot of pain, which he would be, he changes it to a more powerful thing, right? But it starts the cycle all over again. So when you ask me, it’s like, why are we having so much chronic illness? It’s because of the whole philosophy. is the treatment philosophy of mainstream medicine that despises what you and I do. Because we’re… our philosophy from the start is the biggest thing. It’s like… We’re striving for cure. That dirty four-letter word, cure, we’re not even supposed to use it. And yet, if you look it up in Stedman’s Medical Dictionary, it just means a restoration of health. Remission. Everyone’s like, oh, I’m in remission. I’m like, remission is a drug term. It’s a medical term. Again, look it up in a medical dictionary. It is a pharmaceutical term for a temporary pause Or a reduction of your symptom, but because it’s just… symptom suppression, it will come back. It’s… remission is great, I suppose, in… At the end of, like, where you’ve exhausted everything, because I can’t fix everything, I don’t know about you. Dr. Deb 52:41No, I can’t either, yeah. David Jernigan 52:43you know, on my phone consults, I try to always remind people, as much as I get excited about my technologies gosh, I see so much opportunity to fix you. I always try to go, please understand, I’m gonna tell you what most doctors may not tell you on a phone consultation. I can’t fix everything. Dr. Deb 53:03Yeah. David Jernigan 53:03For all of my tricks, I can’t fix everything. Not tricks, but you know, all my technologies, and all my inventions. Phages, too. They are a tool. You know, antibiotics. I think I wrote a blog one time, it should be on my website somewhere, that says, Antibiotics do not… fix… neurological disease, or… I don’t know, something like that. You know, you’re using the wrong tool. I mean, it does what it does. Dr. Deb 53:32Yeah, you’re using a hammer to do what a screwdriver needs to. David Jernigan 53:35Yeah, you know, it’s like it’s… And yet, you can probably tell her… that you’ve had patients, too, that they go, Dr. Jernigan. My throat was so sore, and as soon as I swallowed that antibiotic. I felt better, and I’m, like, going… How long did it take? Oh, it was immediate! I was like, dude, the gel cap didn’t even have time to dissolve, I mean… Dr. Deb 53:58SIBO. David Jernigan 54:00But, it’s not going to repair the tissues that were all raw. kind of stuff. So, I mean, that ulceration of your throat that’s happening, the inflammation, there’s no anti-inflammatory effect of these things. So, I digress a little bit, but phages, too… I wrote an article that’s on the website, that’s setting healthy expectations for phages, because they want… we can see some amazing things happen, things that in my 30 years, I wish I had all my career to do over again, now having this tool. It’s just that much fun. I… when doctors around the country now are starting to use our inducent formulas, there’s, 13 of them now, formulas. For different broad-spectrum illness presentations. I tell them all the same thing, I was like, you are gonna have so much fun. Dr. Deb 54:53That’s exciting. Women. David Jernigan 54:54Winning is fun, you know? I was like. You know, mainstream medicine may never accept this, I don’t know. I feel a real huge burden, though, to do my best to follow a, very scientific methodology. I’ve published as much as I can publish at this time by myself. I never took money from the… the sources that are out there, because what do they do? They always come… money comes with strings. Dr. Deb 55:22Yes, it does. David Jernigan 55:23I don’t trust… I don’t trust… I mean, if you listen to the, roundtable that Our Secretary Robert F. Kennedy Jr. Dr. Deb 55:35Yeah. David Jernigan 55:36On Lyme disease last week the first couple of speakers were, like, pretty legit. I mean, all of them were legit, but I mean, they were, like, senators and congressmen or something like that, I think. And then you have… RFK Jr. himself, who’s legit. Yeah they were fessing up to the fact that, yes, they were suppressing anything to do with Lyme. Dr. Deb 56:00Yeah. David Jernigan 56:00Our… our highest levels of, marbled halls and pillars and… of medicine were doing everything the way I thought they were. They were suppressing me. I was like, how can you ignore the best formulas ever, and still, I think Borreligen, and now, induced native phage therapy are still, I believe, I don’t… I’ve never seen it, I could be wrong. The only natural things that have been documented in a medical methodology. Dr. Deb 56:34Hmm in the natural realm. I mean, all the herbs that we talk about. David Jernigan 56:39You know, there’s one that was really famous for a while, and it said, we gave… so many patients. This product, and other nutritional supplements. And at the end, X number of them were… dramatically better. That’s not research. Dr. Deb 56:57Right. That’s observation. David Jernigan 56:59The trick there was we gave this one thing, and then we gave high-dose proteolytic enzymes, we gave high dose this, we gave high dose that, but at the end of the study, we’re going to point back at the thing we’re trying to sell you as being what did it. Dr. Deb 57:12Which is what we do in all research, pretty much. David Jernigan 57:15Well… Dr. Deb 57:16tried to… David Jernigan 57:17Good guys, I hope. Dr. Deb 57:18Do the way we want, right? In… in conventional… David Jernigan 57:22Yeah. Dr. Deb 57:22Fantastic David Jernigan 57:23Very often, yeah, in conventional medicine, definitely. Yeah. And, it’s kind of scary, isn’t it, how many pharmaceuticals are slamming us with, because they’re… Dr. Deb 57:33Okay. David Jernigan 57:34There’s a new one on TV every day, and there’s. Dr. Deb 57:36Every day, yes. David Jernigan 57:37It’s like, who comes up with these names? They’re just horrible. Dr. Deb 57:40Yeah, you can’t pronounce them. David Jernigan 57:41I want to be a marketing company and come up with some Zimbabwehika, or something that actually they go with, and I’m like, I just made a million bucks coming up with it. I’ll be glad when that’s not on the TV anymore, which… Oh, me too. Me too. Dr. Deb 57:54Dr. Jaredgen, this was really wonderful. What do you want to leave our listeners with? David Jernigan 58:00Well, you know, everyone’s calling for a new treatment. Dr. Deb 58:05Yeah. You bet. David Jernigan 58:08I have done everything I can do to get it out there, scientifically, in peer review, so that if you want to look up my name. Dr. Deb 58:16I published an open access journal so that you didn’t have to buy the articles. Like, PubMed, you have to be a member. If you want to look at a lot of the research, you have to buy the articles. David Jernigan 58:26I’ve done everything open access so that people had access to the information. I honestly created induced native phage therapy to fix my own wife. I mean, I… I was… I used to think I could actually fix almost anything. Gave me enough time. And, I could not fix her. You know, the first 10 years, she was bedridden. Dr. Deb 58:49Wow. David Jernigan 58:50People go, oh, it’s easy for you, Dr. Jernigan, you’re a doctor. Dr. Deb 58:54Oh yeah, right? Yeah. David Jernigan 58:56Oh my gosh, how many tears have been shed, and how much heartache, and how much of this and that. I mean, 90% of our marriage, she was in, bed, just missing Christmas. All the horror stories you hear in the Lime world, that was her, and I could not get her completely well. And, she’s a very discerning woman. I say that in all my podcasts, because it’s. Dr. Deb 59:19Just… David Jernigan 59:16Amazing. It’s like, every husband, I think, should want a wife that’s… Always, right? Not that you surrender your own opinion, but it’s like, it’s… it was literally, I don’t know what, 6 months before the ILADS conference in Boston in 2029… in 2019 that She said, are you going to the ILADS conference this year? And I’m like, I’ve been going for, like, 15, 20 years, however long it’s been going on, and I was like, I’m not gonna go to this one. And, 3 days before the conference, she says, I think you should go. And I go, okay. Like I say, she’s generally right. And that… I bought a Scientific American magazine at the newsstand in the Nashville airport. Started reading a story about phages in that that copped that edition of the Scientific American, and It was a good article, but it wasn’t super meaty, you know. very deep on those, but I just was stimulated. Something about being at elevation. Dr. Deb 1:00:02Yeah. Your own mountains, I don’t know, I get all inspired. David Jernigan 1:00:25And I wrote in the margins and highlighted this and that until it was, like, ultimately, I spent the entire conference hammering this out. And it worked. And it’s been working, it’s just amazing. It’s… We’re over 200 different infections that we’ve… we’ve clinically or laboratory-wise documented. There’s a new test for my GenX called the CEPCR Lyme Panel. like, culture. 64 different types of infections, and I believe right now the latest count is something like 10 for 10 were completely negative. Dr. Deb 1:01:03Wow. David Jernigan 1:01:03These chronically infected people. And so, that hadn’t been published anywhere. So, in my published article, remember I was talking about that 20 out of the 26 were tested as negative for the infection? That doesn’t mean they’re cured, okay? Remember, they’re chronically damaged. That’s how we need to look at it. Dr. Deb 1:01:23funny David Jernigan 1:01:24damaged. You’re not just chronically infected. And, but with 30-day treatment.24 out of the 26 were tested as negative. Dr. Deb Muth 1:01:34That’s amazing. David Jernigan 1:01:35So 92% of the people were negative.Okay? The chances of that happening, when you run it through statistical analysis.The chances… when you compare the results to the sensitivity percentages, you know, the 100% specificity and 92% sensitivity of the…Of the lab testIt’s a 4.5 nonillion to 1 chance that it was a fluke. Isn’t that amazing? Now, nearly… I’m not even sure how many zeros that is, but it’s a lot. Dr. Deb Muth 1:02:08That’s is awesome. David Jernigan 1:02:09Like, if I just said, well, it’s a one in a million chance it was a fluke.Okay.So, lab tests don’t lie. You’re not done, necessarily, just because you got rid of the infections. Now that formula for Lyme has grown to be 90-plusmicrobes targeted in the one formula. So, we figured out we can actually target individually, but collectively, almost like an antibiotic that’s laser-guided to only go after the bad guys that we targeted.So, all the Borrelia types are targeted, all the Babesias, for,the Bartonellas, the anaplasmosis, you name it, mycoplasma types are all targeted in that one formula, because I said.Took my collective 30 years of experience and 15,000 patients.that I would typically see as co-infections and put them into that one formula, so…When we get these tests coming back that are testing for 64, it’s because of that.So, there’s a lot of coolnesses that I could actually keep going and going. Dr. Deb Muth 1:03:15That’s exciting. David Jernigan 1:03:15I love this topic, but I thank you for letting me come on. Dr. Deb Muth 1:03:18Thank you for joining us. How can people find you? David Jernigan 1:03:22Two ways. There’s the Phagen Corp company that is now manufacturing my formulas.That is P-H-A-G-E-N-C-O-R-P dot com. Practitioners can go there, and there’s a practitioner side of the website that’s very beefy with science, and… and all the formulas that were used, what’s inside of all the formulas, meaning what microbes are targeted by each one. Like, there’s a GI formula, there’s a UTI formula, there’s a SIRS formula, there’s a Lyme formula, there’s a central nervous system type infection formula, there’s… And we can keep going, you know, SIBO, SIFO formula, mold formula… I mean, we’ve discovered so many things that I could just keep going for hours, and… Dr. Deb Muth 1:04:05Yeah. David Jernigan 1:04:06About the discoveries, from where it started in its humble beginnings, To now, so… There’s another way, if you wanted to see our clinic website, is Biologics, with an X, so B-I-O-L-O-G-I-X, Center, C-E-N-T-E-R dot com. And, if somebody thinks they want to be a patient and experience this at our clinic, typically we don’t take just Easy stuff. All we see is chronic.Chronic cases from all over the world. Something like 96% of our patients come from other states and countries. And typically, I’ve been close to 90% for my whole career.About 30-something percent come from other countries in that, so… we’ve gotten really good and learned a lot in having to deal with what nobody else knows what to do with. But if you do want to do that, you can contact us. And, if you… If you don’t get the answers from my patient care staff, then I do free consultations. With the people that are thinking about, whether we can help them or not. Dr. Deb Muth 1:05:13Well, that’s excellent. For those of you who are driving or don’t have any way of writing things down, don’t worry about it, we’ve got you. We will have all of his contact information in our show notes, so you will be able to reach out to him. Thank you again for joining me. This has been an amazing conversation. David Jernigan 1:05:30Thank you, I appreciate you having me on. It was a lot of fun. The post Episode 252 – Induced Native Phage Therapy (INPT) & advanced natural therapies first appeared on Let's Talk Wellness Now.

All Praises to the Most High A'HÂYÂH!!!And YASHAYA!!!Yashana in the Highest!!!Call or Text the Prayer, Praise, Testimony and Discussion line!!! 24 hours a day 7 days a week!!!(407)476-7163 !!!We are a Husband and Wife Team!!!Evangelists James and Louise Eads!!!We are Street Evangelists and Online Ministers too. Preaching the Gospel of Christ Yashaya and our Heavenly Father A'HÂYÂH!!!Repent and Follow Yashaya!!! And be Baptized for the Remission of Sins and for the sins of your forefathers!!!Thank you everyone that gives to this Ministry to get the Gosple of Yashaya across the World.We have Pay Pal and Cash App PayPal:Email address is watchmanstreetministry@gmail.com Thank you for your prayers and support https://www.paypal.me/JamesEadsCash App: $Evangelists7

All Praises to the Most High A'HÂYÂH!!!And YASHAYA!!!Yashana in the Highest!!!Call or Text the Prayer, Praise, Testimony and Discussion line!!! 24 hours a day 7 days a week!!!(407)476-7163 !!!We are a Husband and Wife Team!!!Evangelists James and Louise Eads!!!We are Street Evangelists and Online Ministers too. Preaching the Gospel of Christ Yashaya and our Heavenly Father A'HÂYÂH!!!Repent and Follow Yashaya!!! And be Baptized for the Remission of Sins and for the sins of your forefathers!!!Thank you everyone that gives to this Ministry to get the Gosple of Yashaya across the World.We have Pay Pal and Cash App PayPal:Email address is watchmanstreetministry@gmail.com Thank you for your prayers and support https://www.paypal.me/JamesEadsCash App: $Evangelists7

Send us a textWe begin this episode by continuing our discussion of whether a Christian can fall from grace and be lost. We discuss Galatians 5 chapter 1 through 4 where Paul tells the Christians to stand fast. We talk about the implication that a Christian may not stand fast. We move on to notice that Peter warns Christians not to get entangled in the pollutions of the world. This is a clear indication that it is possibility of doing so. We take some time to look at a few of the passages that are used by those who erroneously claim that Christians cannot fall from grace. We move on to discuss the eternal life that a Christian possesses and what this entails. Of course, this includes a discussion of the judgment that all will be subject to by the Lord. We talk about the sins Christians commit and what the Bible says the Christian is to do about it. Jesus tells several parables that are important for us to know that illustrate God's love of His people. We look at these. We close out this episode by talking about sin, its effect upon the Christian, where it comes from and how a Christian can protect from it. Take about 30-minutes to listen in on our discussion. Have your Bible handy so you can verify what we are saying. There is a transcript of this Buzzsprout episode provided for your convenience.

All Praises to the Most High A'HÂYÂH!!!And YASHAYA!!!Yashana in the Highest!!!Call or Text the Prayer, Praise, Testimony and Discussion line!!! 24 hours a day 7 days a week!!!(407)476-7163 !!!We are a Husband and Wife Team!!!Evangelists James and Louise Eads!!!We are Street Evangelists and Online Ministers too. Preaching the Gospel of Christ Yashaya and our Heavenly Father A'HÂYÂH!!!Repent and Follow Yashaya!!! And be Baptized for the Remission of Sins and for the sins of your forefathers!!!Thank you everyone that gives to this Ministry to get the Gosple of Yashaya across the World.We have Pay Pal and Cash App PayPal:Email address is watchmanstreetministry@gmail.com Thank you for your prayers and support https://www.paypal.me/JamesEadsCash App: $Evangelists7

A long-term analysis of major prediabetes trials found that achieving remission or returning glucose levels to normal was associated with over a 50% reduction in cardiovascular death or heart failure, with durable benefits decades later; delaying diabetes without remission did not show similar benefit. A randomized trial in critically ill adults found no difference in 28-day mortality between ketamine and etomidate for intubation, though ketamine increased the risk of cardiovascular collapse. Finally, molecular data showed indoor tanning causes widespread DNA mutations linked to melanoma, reinforcing its carcinogenic risk.

In this episode, we speak with Synary Be, a resilient survivor of acute myeloid leukemia (AML), who shares her powerful journey of enduring three bone marrow transplants over eight years. Diagnosed suddenly in March 2017, Synary's story begins with a high fever that led to a shocking diagnosis: 93% leukemia. From that point on, her life transformed into a series of hospital stays, treatments, and moments that tested her strength and spirit.We learn how her first transplant involved two umbilical cord donors, one from the U.S. and another from Singapore. When that failed to graft, her younger brother flew from Australia to donate for her second transplant—a 50% match. After two years in remission, she relapsed again and required a third transplant, this time from her older brother, right in the midst of the COVID-19 pandemic. With travel restrictions in place, the donor cells had to be processed remotely and shipped to Stanford, showcasing the remarkable role of medical technology in saving lives.Despite being given only a 50% chance of survival for her third transplant, Synary put her trust in her doctors. Though she relapsed again, she now maintains remission through chemo pills. With no long-term data available for this new medication, she continues treatment cautiously and with optimism, trusting in the advancement of medicine.Synary spends some time opening up about the chronic graft-versus-host disease (GVHD) that followed her transplants. She explains its impact on her lungs, eyes, mouth, nails, and skin, detailing both the physical symptoms and the treatments that have helped her reclaim daily life. From scleral lenses to serum tears, to pulmonary rehab and steroid creams, she educates us on the challenges and management of GVHD.Beyond the physical toll, Synary discusses the mental health struggles tied to long-term illness—particularly anxiety from repeated hospitalizations. She emphasizes the importance of therapy, meditation, support groups, and the courage to seek help. Her words serve as a reminder that managing chronic illness includes caring for both mind and body.Synary's story wouldn't be complete without acknowledging her support system. Her husband, who acted as her full-time caregiver through 300 cumulative days of hospitalization, and her three children, endured major sacrifices. Friends and community support filled in the gaps, underscoring that no one should navigate transplant recovery alone.Even in the face of isolation, fatigue, and anxiety, Synary finds joy in simple pleasures: watching Christmas movies, going for walks, and spending time with family. Her message is clear—life is still good. And GVHD, while challenging, cannot take away her joy.Calm App — https://www.calm.comThanks to our Season 19 sponsors, Incyte and Sanofi.https://incyte.com/https://www.sanofi.com/en00:40 - Introduction to Synary Be01:20 - AML Diagnosis and First Transplant03:10 - Transplants and Donor Challenges04:06 - Relapses and Chemo Maintenance06:44 - Living with GVHD12:15 - GVHD Symptoms and Treatments13:40 - Support System and Caregiving15:34 - Isolation After Transplants16:38 - Mental Health & Anxiety19:03 - Coping and Finding Joy20:36 - Final Thoughts and Message of Hope National Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/nbmtLINK Facebook Page: https://www.facebook.com/nbmtLINKFollow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/The nbmtLINK YouTube Page can be found by clicking here.To participate in the GVHD Mosaic, click here: https://amp.livemosaics.com/gvhd Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

News On The Flipside Trump new pole numbers more pic with Epstein seems democrats not thru digging there own graves . Aliens Are Probably Out There, NASA Scientist Says—But There's a Dreadful Reason They Never Call King Charles' Cancer Is Not in Remission, Palace Clarifies: Treatment Moving into ‘Precautionary Phase' Archaeologists Found a Lost Temple in the Sand That Solves a Major Historical Puzzle Christmas brawl erupts in wealthy Massachusetts enclave during holiday celebration McDonald's pulls controversial Christmas commercial within days of being uploaded: 'Offensive from every angle' Entire Russian column destroyed entering Pokrovsk North Korean armored vehicles appear on the Ukrainian frontline Giant 250,000-mile X-ray cloud found around 3i/Atlas, and experts admit they don't understand it yet Trump's signature tax laws could let millions of Americans pay $0 in federal income tax. Here's who can eliminate their 2025 bill completely US sides with Russia and North Korea on UN resolution Israel unleashes Iron Beam laser weapon NASA confirms comet 3I/ATLAS is speeding up in new data Giant structure discovered deep beneath Bermuda is unlike anything else on Earth Russia strikes ports of Odesa and Chornomorsk with ballistic missiles, Turkish cargo ship hit Something weird is orbiting Neptune - and it shouldn't be SSO and Russian partisans cripple two Russian military cargo vessels

All Praises to the Most High A'HÂYÂH!!!And YASHAYA!!!Yashana in the Highest!!!Call or Text the Prayer, Praise, Testimony and Discussion line!!! 24 hours a day 7 days a week!!!(407)476-7163 !!!We are a Husband and Wife Team!!!Evangelists James and Louise Eads!!!We are Street Evangelists and Online Ministers too. Preaching the Gospel of Christ Yashaya and our Heavenly Father A'HÂYÂH!!!Repent and Follow Yashaya!!! And be Baptized for the Remission of Sins and for the sins of your forefathers!!!Thank you everyone that gives to this Ministry to get the Gosple of Yashaya across the World.We have Pay Pal and Cash App PayPal:Email address is watchmanstreetministry@gmail.com Thank you for your prayers and support https://www.paypal.me/JamesEadsCash App: $Evangelists7

Remission is no longer an abstract idea for people living with AiArthritis diseases. Thanks to earlier diagnosis, better treatment options, and growing global awareness, more patients are reaching remission and staying there. In this episode of AiArthritis Voices 360, Health Education Manager Leila P. L. Valete sits down with Neil Betteridge of the Global Remission Coalition to explore what remission truly means and why it is becoming a realistic goal for many. Together they unpack how remission differs from basic disease control and why that distinction is so important for daily life. They also talk through the emotional and practical impact of reaching remission, the role of early action, and the barriers that still prevent many patients from accessing timely care. The conversation highlights what sustainable remission looks like in the real world and how better education, support, and policy attention can help more people get there. Whether you are newly diagnosed or years into your patient journey, this episode offers a grounded and hopeful look at the road to remission and the steps that can make a life-changing difference.   Episode Highlights: What remission really means and how it differs from basic disease control Why remission improves quality of life, mental health, and daily function Key factors that help patients reach remission including early diagnosis and timely treatment Common barriers patients face like limited access to specialists, treatment delays, and lack of information What it takes to sustain remission through monitoring, adherence, and patient support   Links & Resources Global Remissions resources: www.globalremission.org AiArthritis remission information: https://www.aiarthritis.org/remission Have questions about this episode or topics you want to hear us bring to the table? Email us at podcast@aiarthritis.org  Donate to Support the Show: www.aiarthritis.org/donate   Follow AiArthritis on all social media platforms @IFAiArthritis Sign up for our Monthly AiArthritis Voices 360 Talk Show newsletter! HERE   Connect with our Co Hosts: Leila is the Health Education Manager at the International Foundation for AiArthritis. She is a person living with Lupus and Sjögren's disease. She is passionate about inclusion and diversity in health education and meeting individuals where they are at in order to learn in a way that resonates with them.  Connect with Leila: Tiktok: @Lupuslifestyle.lei   Neil Betteridge developed juvenile arthritis at age three, an experience that shaped his lifelong commitment to advocating for people with chronic diseases. He has led major patient organizations in the UK and globally, including serving as CEO of Arthritis Care and now as Senior Director of the Global Alliance for Patient Access, where he also chairs the Global Remission Coalition. With decades of experience in public affairs and patient engagement, Neil has advised health ministers, worked with the Royal College of Physicians, and held key leadership roles in international networks such as the Global Alliance for Musculoskeletal Health and EULAR. His work continues to advance policy, access, and better outcomes for people living with chronic inflammatory conditions. Connect with Neil: Website: www.globalremission.org X/Twitter: https://x.com/Neil_Betteridge

There are a bunch of stories that testify that those on the other side of the veil are being taught and ministered to and seeking repentance.  It's our privilege to be a part of that great work!If you'd like to view the video that goes with the podcast, click here!

In this inspiring episode, Dr. Isabelle Amigues sits down with Erica Canzler, who shares her journey from a life-changing rheumatoid arthritis diagnosis in 2015 to complete remission—and finishing the legendary Leadville 100 race. Erica opens up about the frustrations of conventional care, the difference holistic and concierge medicine made at UnabridgedMD, and how healing means more than just physical health. Dr. Amigues and Erica discuss the importance of patient autonomy, hope, and the power of treating the whole person. If you or someone you love is facing a rheumatologic diagnosis, this episode is a must-listen for encouragement and practical advice.

Today, I'm joined by the innovative Jon Hacker, whose name couldn't be more perfect for the biohacking space. While his family hacks computers, Jon decided to hack something a bit messier—the human mind. After growing up with severe OCD and witnessing the rising tide of global anxiety, he became obsessed with one question: Why are we all stuck in fight or flight, and what can we actually do about it?   Use code NAT at https://zenbud.health/nat for 20% off   Episode Timestamps: Introduction to Longevity Podcast and Host ... 00:00:00 The Rise of Anxiety and Mental Health Innovation ... 00:05:19 Why Modern Society Fuels Anxiety ... 00:07:18 Impact of Chronic Stress on Health ... 00:08:51 Barriers to Managing Anxiety with Habits Alone ... 00:17:17 CBT and the Need for Better Tools ... 00:19:27 Vagus Nerve: What It Does and Why It Matters ... 00:20:37 Zenbud: Ultrasound vs. Electrical Stimulation ... 00:28:58 Zenbud Headset Experience and Simplicity ... 00:34:25 Zenbud's Role in Stress Resilience and Longevity ... 00:47:45 Purpose, Mindfulness, and the Future of Biohacking ... 00:50:55 Zenbud: Key Safety Points and Adoption Challenges ... 01:01:08 Zenbud as "An Off Switch for Stress" and Closing ... 01:02:52 Final Tips, Special Offer, and Outro ... 01:03:30   Our Amazing Sponsors: Sunlamp (BTS2) by Mitolux - When your skin makes vitamin D from UVB light, it also creates natural companion molecules that help your body use it smarter—so you're not just boosting levels, you're activating your biology the way nature intended. Visit mitolux.com/NAT10. You'll receive 10% off! NAT10 will be automatically applied at checkout.   NEW Timeline Gummies: Urolithin A supports muscle strength and cellular energy. It's about improving how your body functions at the source. Mitopure is the only clinically proven Urolithin A, giving you six times more than you'd get from a glass of pomegranate juice. Visit Timeline.com/nat20 and use code nat20 for 20% off your purchase.   Probiotic Breakthrough by Bioptimizers - uses a stress-tested Lactobacillus plantarum strain that showed over 30× greater survival in bile and intestinal fluid vs. generic strains. Save 15% at bioptimizers.com/bionat and use code BIONAT for 15% off any order.   Nat's Links:  YouTube Channel Join My Membership Community Sign up for My Newsletter  Instagram  Facebook Group

Rockstroh examines emerging challenges in HIV care, including COVID-19 and mpox, novel therapies, and lessons from Europe's care model. Explore the possibilities of shifting from disease management towards long-term remission and functional cure. Timestamps: 00:00 – Introduction 00:45 – COVID-19 lessons 05:02 – Mpox challenges 07:42 – Novel therapies 12:56 – Improving care 15:39 – Remission or cure?

Alle Informationen zur Carnivoren Ernährung unter www.carnitarier.de. ______________________________________________ Herzlichen Dank an unsere WERBEPARTNER: www.carnivoro.eu: Supplemente rund um die Carnivore Ernährung Mit dem Gutscheincode CARNITARIER erhältst du 10 % Rabatt auf deinen ersten Einkauf! Affiliate Link: www.carnivoro.eu/carnitarierinwww.kaufnekuh.de: Fleisch aus artgerechter Haltung mit fairen Preisen für Landwirte Mit dem Gutscheincode CARNITARIER erhältst du 10 € Ermäßigung auf deinen Einkauf ab 50 €. www.mindful-meat.com: Hochwertiges Hirschfleisch aus den Wäldern Deutschlands. Mit dem Gutscheincode CARNITARIER erhältst du 10 € Ermäßigung auf deinen Einkauf. www.pemmican-shop.de: Europas einzige originale Survival Beef Bar – Made in Germany. Mit dem Gutscheincode CARNITARIER erhältst du 10 % Ermäßigung auf deinen ersten Einkauf.www.theminerals.de: Beste Elektrolyte für die Umstellung auf Keto und für Carnivoren, die viel Sport treiben. Mit dem Gutscheincode CARNITARIER erhältst du 10 % Ermäßigung auf deinen Einkauf. ______________________________________________Folge 208: Carnivore gegen Autoimmunerkrankungen – Bastian HölscherCarnivore ist eine Eliminationsdiät. Wer Probleme mit Autoimmunerkrankungen oder chronischen Magen-Darm-Erkrankungen hat, sollte möglichst viele Lebensmittel eliminieren, die einem nicht guttun. Bastian Hölscher, funktionieller Mediziner, hat selbst seine chronisch entzündliche Darmerkrankung mit einer Paleo-Ernährung, also nahezu einer Carnivoren Ernährung in Remission gebracht. Bei jedem Lebensmittel sollte man sich fragen, welche Nährstoffe man daraus ziehen kann und welchen Schaden es im Körper anrichten könnte. Kakao hat zum Beispiel einen sehr hohen Gehalt an Oxalsäure, die sich in unserem Körper ansammeln kann. Ausleitungssymptome von Giftstoffen, auch von Schwermetallen können aber auch Probleme hervorrufen. Kohlenhydrate können gezielt eingesetzt werden, je nachdem, wie stark sie durch Bewegung wieder abgebaut werden. Wer Carnivore macht, der denkt einfach um. Er verlangt nicht extra Substanzen oder Medikamente gegen die Beschwerden, sondern er streicht Lebensmittel, die die Beschwerden verursachen. Man geht also der Ursache auf den Grund. Carnivore ist im Grunde wie ein Fasten, aber eben eine Form, die man auf Dauer durchführen kann und die einem alle Nährstoffe liefert.Ihr könnt Bastian Hölscher erreichen unter www.praxishoelscher.de oder auf  Instagram unter @bastianhoelscher._____________________________________________Fleischzeit ist der erste deutschsprachige Podcast rund um die carnivore Ernährung. Hier erfahrt ihr Tipps zur Umsetzung des carnivoren Lifestyles, wissenschaftliche Hintergründe zur Heilsamkeit sowie ökologische und ethische Informationen zum Fleischkonsum. Eine Übersicht über alle Folgen findet ihr hier: www.carnitarier.de/fleischzeitpodcastAndrea Siemoneit berichtet nach über sechs Jahren carnivorer Ernährung über ihre Erfahrungen und Erkenntnisse. Außerdem interviewt sie andere Carnivoren und Wissenschaftler.Ihr findet sie auf Instagram unter @carnitarier.deHandbuch der Carnivoren Ernährung: www.carnitarier.eu Haftungsausschluss:Alle Inhalte im Podcast werden von uns mit größter Sorgfalt recherchiert und publiziert. Dennoch übernehmen wir keine Haftung für die Richtigkeit, Vollständigkeit oder Aktualität der Informationen. Sie stellen unsere persönliche subjektive Meinung dar und ersetzen auch keine medizinische Diagnose oder ärztliche Beratung. Dasselbe gilt für unsere Gäste. Konsultieren Sie bei Fragen oder Beschwerden immer Ihren behandelnden Arzt.

Guest Dr. Sundar Jagannath and host Dr. Davide Soldato discuss JCO article "Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma," and the efficacy of CAR-T cell therapy in patients with heavily pretreated RRMM (relapsed/refractory multiple myeloma). TRANSCRIPT Dr. Davide Soldato: Hello and welcome to JCO After Hours, the podcast where we sit down with authors from some of the latest articles published in the Journal of Clinical Oncology. I am your host, Dr. Davide Soldato, medical oncologist at Ospedale San Martino in Genoa, Italy. Today, we are joined by JCO author, Professor Sundar Jagannath, Professor of Medicine at the Icahn School of Medicine at Mount Sinai and the Tisch Cancer Institute. He also serves as Network Director for the Center of Excellence for Multiple Myeloma, and he is an internationally recognized expert in the field of multiple myeloma. Today, we will be discussing the article titled, "Long-Term Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma." Thank you for speaking with us, Professor Jagannath. Dr. Sundar Jagannath: Thank you for having me, Dr. Davide Soldato. It is a pleasure to be here. JCO is a highly recognized journal among the oncologists, so I am very happy and privileged to be here today. Dr. Davide Soldato: Thank you so much for being with us. So, I wanted to start a little bit with the rationale of the study and the population that was included in the study. So, the trial that we are discussing, CARTITUDE-1, was already published before, and we observed very good results with a single infusion of cilta-cel. So we had previously reported a median progression-free survival of 30 months, and median overall survival was not reached. So, I just wanted to ask you if you could guide us a little bit into the population that was included in the study and also explain a little bit to our listeners what is the drug that we are discussing, cilta-cel. Dr. Sundar Jagannath: It is a CAR T-cell. This is a patient's own lymphocytes, which goes through apheresis and is sent to the company, where they modify it and introduce the B cell receptor. In this case, you know, there is a heavy chain gene receptor for the BCMA, and in cilta-cel, there are actually two receptor sites on each molecule, or there are two binding domains on each receptor molecule. So, it is considered to be quite efficacious. As you reported, the earlier results that the patients who participated, 97% of the patient responded. Now, you asked about the patients who participated in the clinical trial. This clinical trial was conducted between July of 2018 and October of 2019. At that time, this was a phase 1b/phase 2 trial, and the whole idea was to take patients who had relapsed all the available treatment regimen so that these patients were considered to have, in the unmet medical need situation. So, what does that entail? That means the patient should have been exposed to a proteasome inhibitor, to an immunomodulatory molecule, and to an anti-CD38 monoclonal antibody and should have received at least three or more prior lines of therapy and should be actually progressing on their last line of therapy. So with that requirement, if you look at it, the median number of prior therapy on the patients who participated was actually six. So patients were heavily pretreated. They had exhausted all available treatment options. So, they can participate in this clinical trial. And if not, there have been real-world evidence, such as LocoMMotion, which had reported what is the outcome for such a patient if they were treated outside of this clinical trial, if they were treated with the then available regimen. Their median progression free survival would have been only 3 months, and most patients would have lost their life within a year. So, this was truly an unmet medical need with patients in a very difficult clinical situation. Let's put it that way. So, those were the patients who participated in this particular trial. Dr. Davide Soldato: Thank you very much. And as we mentioned before, the results that were obtained in this clinical trial were really very interesting. And now, in this issue of the Journal of Clinical Oncology, you are reporting data with a longer follow up. So we are actually at more than 5 years of follow up for the patients included in this trial. So, I just wanted a little bit of insight into why you decided to report these long-term outcomes and what type of information do you think you could provide with this study to the medical community? Dr. Sundar Jagannath: This is very important because this was a clinical trial that was done in patients who were, as I said, in unmet medical need. Most of the patients had prior stem cell transplantation, had gone through a proteasome inhibitor. Many of them have had both Velcade and carfilzomib treatment. Most of them had been exposed to lenalidomide and pomalidomide. And as required, all of the patients had to have had prior exposure to anti-CD38 monoclonal antibody or daratumumab. So, the patients were heavily pretreated. Typically, TIL CAR T-cells came into the field at this particular moment, until then, we were developing small molecules, and they usually would have a PFS of 3 months and median life expectancy of a year, the overall response rate of 30%, and that is how, if you look back, that is how carfilzomib was approved, that is how pomalidomide was approved. So, the drugs which were approved, including daratumumab, you know, the response rate was in the same ballpark. So you would see that most agents, single agents, would have had a response rate in the neighborhood of 30%, the progression-free survival would have been between 3 to 5 months or 6 months at the most, and the life expectancy was short. And here comes a drug, and when I was following the patients at Mount Sinai, I found that there were a subset of patients, they got one-time treatment and they were in complete remission, no trace of cancer with annual evaluation with PET CT and bone marrow evaluation for MRD. So, I said this is remarkable, and this needs to be reported. And I went to the Janssen and company, and they agreed to review the entire experience. This is remarkable that 32 of the 97 patients, or one third of the patients, were alive and progression-free. This is unheard of for any clinical trial until now, that the patient will be progression-free, one third of the patients on a clinical trial will be progression-free, in the late stage of their disease. So that is the most important impact. And that is why this 5-year follow-up results were presented. Dr. Davide Soldato: Thank you very much. That was very clear. And as you said, we are speaking about a population that was heavily pretreated, that had exhausted all type of treatment options outside of a clinical trial. And as you said, one third of the patients was alive and progression-free after 5 years from being included and infused inside of the study. So, considering this population that, as we said, had received all treatment options, I was wondering if you observed any kind of differences in terms of disease characteristics when looking at these patients that had exceptional response, so, alive and progression-free at 5 years, and the patients that sadly had developed a progression after the infusion in the study. Dr. Sundar Jagannath: This is very important because we wanted to see who are the patients who are having this exceptional outcome. And we looked at all the 97 patients. If we look at all the patients, we saw that there were initially, out of the 97, 17 patients died earlier in the disease course due to treatment related complications, etc. But there were about 46 patients who had progression of disease and 32 patients, or one third, were alive without progression of disease. Then we looked at the 46 patients who had progression of disease. Of them, we found that 30 had disease progression and its complication, and there were actually 13 patients who were still alive even after progression of disease. So we decided to compare these 46 patients who had progression of disease versus 32 patients who had no progression of disease to see what is the difference. To our surprise, the age was similar, male, female distribution was similar. High-risk cytogenetics, which we would have thought, you know, that is why we say high-risk disease, the term, high-risk cytogenetics was equally distributed. That was really a surprise. Number of lines of prior therapy, number of exposure to drugs, all of that was the same. So that was also interesting. But a theme did emerge. Patients, in general, tend to have lower burden of disease who had the exceptional outcome. But there is one which we considered as bad, the extramedullary disease. Multiple myeloma being a blood cancer, it is usually in the bone marrow. When it starts growing outside of the bone marrow, the extramedullary disease, usually it portends poor prognosis. But we were surprised that actually there were an equal number of extramedullary disease patients even in the long-term survivor as those who had progressed of disease. So the most important takeaway was patients who had lower burden of disease, they had less number of myeloma cells in their bone marrow, percentage wise, and the soluble BCMA level was lower. Soluble BCMA is an indirect measure of the amount of plasma cells in the patient's body. It is like a tumor burden. So they were low. So, this was an important finding because it has future ramification, as you can understand. If this treatment is made available earlier in the disease course of the patients, where we are able to control the disease better, then more patients are likely to have such wonderful outcomes as one third of the patient experience in the late stage of the disease. Dr. Davide Soldato: So, you already mentioned soluble BCMA as a marker of potentially better prognosis as being correlated to a lower volume of disease. I was wondering if you could give us some more information about the biomarkers that you evaluated in the study. For example, you evaluated a little bit the CAR T expansion kinetics and also some others that I think could be interesting and could point to some population that experienced such important benefit. Dr. Sundar Jagannath: That is a very important point because CAR T-cell, it is a live cell and its efficacy depends upon how well the CAR T-cell is going to function. And then, you know, the patient undergoes apheresis. This is a patient's own lymphocyte. So first and foremost is who would generate good CAR T-cell. Those who have plenty of lymphocytes at the time they are coming for apheresis. This is likely to happen earlier in the course of the disease than in patients who have gone through numerous lines of therapy and exhausted. So, in this particular trial, of course this was in late stage of the disease, and so we were able to show patients who had lower number of T cell in circulation, and the way to measure is if they had more neutrophils and less lymphocytes. So that is what is called as a higher T cell over neutrophil, they did better. If they have more neutrophil than T cells, then they did not do well. So, procurement. The second one is also whether the T cells are more naive, you know, not exhausted T cells. So more naive T cells, if you are able to procure from the patient, they did very well. Now, after the CAR T-cell manufacture, then the expansion, when you put it back into the patient, if the T cells expand very well, so that the effector, that is the CAR T-cells to the tumor ratio is good, so there are more effector cells, the CAR T was able to expand and the amount of tumor was less, then the efficacy was very, very good. As I said, the patients in this group, those who had a lower burden of disease, they did better, and that is because of the CAR T-cell expansion, so the effector to the target ratio was favorable. So that is another important. And then there are also the type of CAR T-cells, having CD4 T cells with central memory phenotype at the peak expansion also makes a difference. So all of that matters. But this is important because the efficacy of the CAR T-cell, it is persistent, long persistent and keeping the cancer down. Its ability to get rid of the cancer completely at the first go around because usually we are not able to detect the CAR T-cells beyond 6 months in the majority of patients and very rarely after a year or two. So it is very uncommon to find the CAR T-cells in circulation or even in the regular bone marrow evaluation. So, efficacy, the expansion, having naive T cells, having good effector to target ratio and more central memory kind of T cell, because if it is all effector T cell, they will get quickly utilized and get exhausted, whereas the central memory cells can expand more and give more effective CAR T-cells. Dr. Davide Soldato: Thank you very much. I was wondering if you could guide us a little bit into what is your opinion regarding the positioning of CAR T-cells given all of these logistics that is necessary compared, for example, with bispecific antibodies against BCMA, which have the same target, but they do not have all of these logistics before being administered to the patient. Dr. Sundar Jagannath: That is a very important question, how to sequence these treatments now that we have two BCMA-directed CAR T-cells available. We have three BCMA-directed bispecific and one GPRC5D-directed bispecific antibodies are available. And so the question comes in for at least the currently approved CAR T-cell therapy, there is an obligatory time. You have to go through apheresis and you have to ship to the company, and there is a manufacturing time, roughly about 2 months before they can receive it. During that time, you want to make sure the patient's disease is under control. So that is a given. There are several ways to look at it when we evaluate the patient and talk to the patient. One good thing is now the two CAR T-cells which are approved, one is cilta-cel we talked about, and the other one is ide-cel. Ide-cel is approved in earlier line of therapy, two or more prior lines of therapy, and cilta-cel is approved in patients who have failed one line of therapy and who are lenalidomide refractory. So, the treatment of CAR T-cell is available earlier. And as I said, when you administer CAR T-cell earlier, you are able to keep the disease burden down, and it is a one and done deal. There is a better quality of life for the patient, and you are able to produce long, durable remission and potentially a cure. Now coming to the bispecific, they are currently available in later lines of therapy. So if you look at it from a patient's perspective, you can use the CAR T-cell earlier and then go through the bispecific therapy. But if the patient comes with relapsed refractory myeloma and has not used the CAR T-cell therapy and has not used the bispecific therapy, then the physicians have to decide which one they want to use. If somebody's disease is rapidly progressing and they need immediate tumor reduction and they have already exhausted all available therapy, then going through BCMA bispecific therapy is quite appropriate. And secondly, CAR T-cell therapy is generally given to somewhat physically more fit patients, whereas bispecific therapy, because you are giving antibody at step-wise dosing in this patient, and you have the ability to stop at any particular dose and then come back and redose, whereas CAR T is, you just give it to them one time, you have a lot more control. So intermediate frail or even frail patients can go through bispecific therapy, whereas it would not be in the best interest of the patient to go through a CAR T-cell therapy when they are frail. So that is another important point. But from the information available, when the patient goes on a BCMA bispecific therapy and they start progressing on treatment, usually it is their T cells are exhausted or the BCMA is no longer expressed on the tumor cells. So coming with CAR T-cell later on is usually not effective, whereas giving CAR T-cell earlier, if the patient relapses later, they have good T-cell function and most of the time the BCMA is still expressed. So you are able to give the BCMA to the maximum benefit by using the CAR T first and BCMA later. So if somebody asked me how to sequence this, just off the bat, you will say CAR T first, BCMA bispecific second. But as I said, there are unique situations. Then there is another potential that is happening. You can change the target. You can use a BCMA against GPRC5D to reduce the tumor, and then go ahead and consolidate it with a CAR T-cell therapy. That is also possible. You are changing the target from GPRC5D to BCMA, the tumor is already down, so the patient is likely to benefit. So these are all newer treatment options which have become available to the physician. So they will have to look at individual patients and decide what is the best course of action for that patient. Dr. Davide Soldato: So, I just wanted to close a little bit with your opinion about how these results translate into clinical practice. So considering this outstanding 5-year data that we have seen, one third of the patients who are alive and progression-free after a single infusion of cilta-cel, do you think that we could start to think about functional cure even in patients who have a diagnosis of relapsed refractory multiple myeloma? Dr. Sundar Jagannath: My feeling is this is important because in this particular study which is published, 12 patients who were followed at Mount Sinai out of the 32 patients who are alive and progression-free, 12 were followed at Mount Sinai. And they were evaluated every year with bone marrow MRD testing by clonoSEQ in 11 of the 12 patients, and one was by multiparametric flow cytometry. So most of them were 10 to the minus 6, not even one in a million cancer cells, and all of them had functional imaging, which is called PET CT every year. So these were patients who had no evidence of disease that we could detect with the technology available today, serologically, in the bone marrow, or anywhere else in the body with a PET CT. They were found to be disease free after a single infusion of cilta-cel. So, that would be almost to the definition of a cure because if you look at cure as a definition for any cancer, cure is defined as a state of complete remission with no trace of cancer that persists over a period of 5 years or longer without maintenance. And that will be applicable for breast cancer, lymphoma, leukemia. So it is a general statement. And if we use that in myeloma too, then I could say that these 12 patients from my center, we proved that they are cured of their myeloma. They are not functionally cured. You've got to remember, there is only cure. That was the definition across all diseases. So there is nothing like a functional cure. They are cured of myeloma. So is myeloma curable? This is the first time we are looking at that. We do know, every physician treating myeloma that there are patients out there, 10 year and beyond, without evidence of disease. This has been published by University of Arkansas, Bart Barlogie's group, who has been saying that myeloma is a curable disease for a long time. And many others have shown long-term follow up. But this one in a late stage disease, we were able to show that they were one treatment with no maintenance. All other studies have been in newly diagnosed myeloma patients. Nobody has shown in late relapse patients on a clinical trial a third of the patient will be progression-free. And 12 of them who were studied were actually disease free. So they were cured of the disease. So if we accept that, then the next question is, first step towards cure is achieving complete remission. They should have no monoclonal protein by any technology you want to use, no measurable residual disease using next gen sequencing or clonoSEQ, and functional imaging whole body PET CT or whole body MRI. So that is important, definition of the complete remission. And then it has to be sustained. That is something the IMWG and IMS, International Myeloma Society, they will have to come together for a consensus. How many years should they be followed and should be in this kind of status with no trace of cancer? Is it, 3 years are enough? 4 years enough? 5 years is enough? For me, I said in this paper, 5 years is a good definition for achieving a potential cure. Then you use the term 'functionally cured'. I have a problem with functionally cured and operationally cured or whatever. Functionally cured was originally put out by Paiva from Spain. There were 8% of newly diagnosed myeloma patients who have, after they go get treated, they will have an MGUS like phenomenon, a small amount of paraprotein detectable, and they are only 8%. And he said that these patients could be off treatment and the disease does not progress. But the problem is when you are giving treatment like maintenance therapy continuously until progression, you do not know exactly who is in the MGUS situation. So you have to have done sophisticated flow cytometry like Paiva did, and it is not quite clinically applicable. So functionally cured applies only for 8% of the people, so it should go out of the vocabulary. Then you can say 'operationally cured'. These are the patients traditionally Bart Barlogie and others showed that they have a large number of patients who have been followed for 10 years with no recurrence of disease, not on treatment. But in those days, they did not have MRD PET CT and all of them done systematically. So that is why they had to come up with a situation where they said they were operationally cured. So yes, myeloma patients have been cured since auto transplant was introduced. I completely agree. It is not new to the CAR T-cell therapy. But the beauty of the CAR T-cell therapy was it was in relapsed refractory myeloma, unmet medical need, number one. Number two, they were studied systematically. It was a clinical trial adjudicated by FDA and EMA for drug approval, cilta-cel was approved. So these patients were carefully followed, and it was a multi-center study. And in that group of patients, we were able to show patients- So, I think this would indicate cure is a reality in myeloma, and as these kind of treatments, immunologic treatment, either it is a CAR T-cell therapy or BCMA bispecific or whatever, there is a chance more patients are likely to be cured, and these treatments have to move forward and so that we are looking towards a cure. That is the beauty of it, and I just thank you for asking and also throwing in this so-called functionally cured, which people like to use casually, and I say it is time to talk more cure and not stuck with functionally cured because that does not allow the field to progress. Dr. Davide Soldato: Thank you very much. That was very interesting. Dr. Sundar Jagannath: And provocative. Dr. Davide Soldato: A little bit, but I think that we needed to close the podcast with this kind of reflection coming from someone who is an expert in the field, as you are. So, I really wanted to thank you for joining us today and for sharing more on your article, which is titled, "Long-Term Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma." If you enjoy our show, please leave us a rating and a review and be sure to come back for another episode. You can find all ASCO shows at asco.org/podcasts. Dr. Sundar Jagannath: Thank you. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.      

Interview with Giselle Corbie, MD, MSc, Associate Editor of JAMA Internal Medicine, and Lynda H. Powell, PhD, author of Lifestyle Intervention for Sustained Remission of Metabolic Syndrome: A Randomized Clinical Trial. Hosted by Eve Rittenberg, MD. Related Content: Lifestyle Intervention for Sustained Remission of Metabolic Syndrome

Interview with Giselle Corbie, MD, MSc, Associate Editor of JAMA Internal Medicine, and Lynda H. Powell, PhD, author of Lifestyle Intervention for Sustained Remission of Metabolic Syndrome: A Randomized Clinical Trial. Hosted by Eve Rittenberg, MD. Related Content: Lifestyle Intervention for Sustained Remission of Metabolic Syndrome

On Par sits down with Sam Eppy to unpack Juju's Mission to Remission, a 501(c)(3) charity golf tournament for families fighting pediatric leukemia. This year's event is set for November 21 at Bay Tree in Melbourne, Florida!In this episode:• How year one raised about $50K for families facing pediatric cancer, and why the team formed a 501(c)(3) to do it right• How grants and matching gifts opened up after going nonprofit, plus simple steps to qualify• Smart charity golf sponsor mix vs foursome pricing that fills the field and funds the cause• Crowd-favorite activations that lift donations, drone golf ball drop, AR-15 golf-ball launcher, fun putting games.• Easy volunteer roles and swag ideas that keep the tournament smooth and profitable• How to plan a charity scramble at your course, registration flow, day-of timeline, checkout tipsIf this story moved you, help us help more kids. Join us at Bay Tree in Melbourne on November 21, sponsor a hole, or share this with a golfer who cares. Watch the full episode, hit Subscribe, and leave a comment with one small way you can pitch in!#golf #golftournament #charitygolf #charity  #pediatriccancer  #onparpodcast  #melbourneflorida #fundraiser #golfcourse #golfpodcast #podcastshow #SamEppy

(00:00:00) Navigating Disruptions and Resilience (00:04:28) Leadership Challenges in Uncertain Times (00:07:03) Communication: The Key to Team Performance (00:11:17) Understanding Generational Differences in the Workplace (00:13:17) The Role of Empathy in Leadership (00:15:34) Building Resilience in Leadership (00:20:45) Connecting Daily Work to a Larger Purpose In this conversation, Maureen O'Brien, CEO of the Global Wisdom and Leadership Forum, discusses the challenges leaders face in today's uncertain business climate. She emphasizes the importance of resilience, effective communication, and empathy in leadership.O'Brien shares insights on generational differences in the workforce and the need for leaders to connect their teams' daily work to a larger purpose. The discussion highlights practical steps leaders can take to foster a culture of innovation and adaptability within their organizations.Thank you for listening and please take a moment to subscribe, rate, and review our show on your favorite app.To get a hold of us here at Keepin' The Lights On, please email: podcast@graybar.comYouTube Version: https://youtu.be/NEufR_-TZcAGlobalWLF Webiste:  www.globalwlf.comHBDI (Herrmann Brain Dominance Instrument):  https://www.globalwlf.com/leadership-developmentMaureen's Linkedin: https://www.linkedin.com/in/maureenobrienceo/Maureen's book:  “26 Points of Light” – Illuminating One Cancer Survivor's Journey from Diagnosis to Remission”   https://www.amazon.com/Points-Light-Illuminating-Survivors-Diagnosis/dp/1734959010In 26 Points of Light, supporters across O'Brien's community of care—family, friends, coworkers, extended family, and even medical staff—offer their unique experiences of the journey they walked with Maureen and share the knowledge and inspiration they gained along the way. You'll learn:How each caregiver was uniquely impacted by the diagnosisWhy the nurse–patient relationship is so important to anyone undergoing recoveryHow to "quarterback" a loved one's caregiving teamWhy true belief in cancer remission is crucial for both patient and support systemWhy whatever you have to give is exactly the right thing to offerWith its multitude of voices and perspectives, 26 Points of Light is a cancer caregiver book like no other. If someone you love has received an unexpected diagnosis, this book will help you deliver constant, crucial encouragement. And for those experiencing it firsthand, it will illuminate their true impact on others and remind them that they are not alone.Maureen's BIO: Maureen O'Brien is a nationally recognized speaker, bestselling author, and the CEO of the Global Wisdom & Leadership Forum. With over 30 years of experience in leadership, sales, and business ownership—including in construction and the skilled trades—Maureen brings a unique, real-world perspective to the challenges leaders face today.A Stage IV cancer survivor and the author of “26 Points of Light: Illuminating One Cancer Survivor's Journey from Diagnosis to Remission,”  Maureen's personal story fuels her professional mission: helping others lead with courage, clarity, and resilience. She is the creator of Point of Light Leadership™, a practical framework for navigating change and inspiring teams in high-stakes environments.Her core message is clear: Resilient leadership isn't just about bouncing back—it's about lighting the way forward for others.ALL PROCEEDS OF THE BOOK GO TO CANCER RESEARCH AND PATIENT CARE. TakeawaysResilience is crucial for leaders in today's challenging environment.Effective communication is key to resolving team dynamics.Leaders must practice self-awareness to understand their impact on teams.Empathy has become a vital skill for effective leadership. Generational differences can create challenges in the workplace.Leaders should encourage innovation and risk-taking among their teams.Understanding the bigger picture can motivate teams to perform better.Leaders need to connect daily tasks to a larger purpose.Continuous learning is essential for resilient leadership.Taking a pause can help leaders break free from preconceived notions.

In the ongoing search for an HIV cure, promising evidence suggests that early treatment of infants might help achieve lasting HIV remission: the IMPAACT P1115 study is designed to investigate that potential. We talk to a lead investigator about what we know so far.Read the full article: www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(25)00189-4/fulltextContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

In this hope-filled episode of the UnabridgedMD Podcast, Dr. Isabelle Amigues sits down with Cliff—a former patient—to trace his journey from sudden, debilitating pain and months of uncertainty to full remission and a return to the life he loves. After being dismissed and delayed elsewhere, Cliff found UnabridgedMD, received an accurate diagnosis of polymyalgia rheumatica (PMR), and followed a clear, compassionate plan: calm the “fire” of inflammation, treat decisively, and taper safely. Within a few months he was off steroids, symptom-free, and cleared to travel to Africa—proof that partnership, precise listening, and a treat-to-target mindset can change everything.

In this bonus episode, Dr. Kahn sits down with Dr. William Hsu, Chief Medical Officer at L-Nutra (Prolon) and former Harvard Medical School faculty member, for a fascinating look at how fasting can help put Type 2 diabetes into remission. Dr. Hsu explains why muscle mass is crucial for managing diabetes — it's where glucose gets absorbed — and how the Fasting Mimicking Diet (just five days a month for six or more months) can lead to incredible results. The program not only supports blood sugar control but also helps preserve muscle and target belly fat, which is exactly what you want from healthy weight loss. Check out the programs mentioned in the episode:

For full show notes visit https://www.janeperrone.com/on-the-ledge/2025/10/24/episode-306-the-atlas-of-deadly-plants My new book The Atlas of Deadly Plants is out this week, published by Greenfinch, so I thought I'd celebrate by offering up a series of mini-podcast episodes digging into some of the themes and facts from the book - just in time for Halloween! In this mini-ep I talk about two terms you might hear in connection with plant poisonings - treacherous remission and therapeutic range. Want to buy a copy right now? Click here. Check out Legends of the Leaf, my book on houseplants and my houseplant cards Houseplant Gardener in a Box here. Support On The Ledge on Patreon: https://www.patreon.com/ontheledge Follow Jane Perrone on Instagram: https://www.instagram.com/j.l.perrone

Mel Burbank, founder of Alcohol Free Females, shares her sobriety journey and her mission to empower high-performing women to embrace an alcohol-free lifestyle through reinvention. She discusses the concept of spontaneous remission and how she teaches clients to achieve sobriety through her program.With a background as a certified integrative health and CBT coach, a longtime single mom, and a female entrepreneur, Mel left alcohol behind to create her dream life. With an MBA and over 20 years of experience in women's wellness, fitness, and identity transformation, she provides her clients with the framework to build a life on their own terms-with clarity, confidence, and zero compromise.You can connect with Mel Burbank on Instagram @alcoholfreefemales

DisclaimerThis podcast represents the opinions of Your Life, Reset and guests to the show. The content here should not be taken as, or considered a substitute for, medical advice, diagnosis and/or treatment, for either yourself or others, including but not limited to individuals you may be treating. The content here is for informational purposes only, and because each person is unique, please consult your medical provider for any medical questions or if you have, or suspect you have, a medical problem. In no way does listening, reading, emailing or interacting on social media with our content establish a doctor-patient relationship.Views and opinions expressed in the podcast are our own and do not necessarily represent that of our places of work. While we make every effort to ensure that the information we are sharing is accurate, we welcome any comments, suggestions, or correction of errors.Privacy is of the utmost importance to us. Where appropriate, the people, places, and scenarios mentioned in the podcast may be changed to protect patient confidentiality.This podcast should not be used in any legal capacity whatsoever, including but not limited to establishing “standard of care” in a legal sense or as a basis for expert witness testimony. No guarantee is given regarding the results or accuracy of any statements or opinions made on the podcast.This entire disclaimer also applies to any guests or contributors to the podcast. Under no circumstances shall any guests or contributors to the podcast, or any employees, associates, or affiliates of Virta Health be responsible for damages arising from use of the podcast.If you find any errors in any of the content, please send a message through our form here: https://virtahealth.zendesk.com/hc/en-us/requests/newThis podcast is owned by Virta Health. The contents of Your Life, Reset and show notes are all copyrighted Virta Health. All posts, podcasts, and show notes that are distributed to the public for free can be re-distributed via hard copy or electronic copy for free ONLY if Virta Health is included as the acknowledged author within the actual media that is re-distributed.Your Life, Rest: privacy policy (link) and terms and conditions (link).

SummaryThe conversation delves into the importance of discerning truth within the Christian faith, emphasizing the need to question personal interpretations of the Bible to align more closely with God's knowledge.Takeaways-To discern truth, one must eliminate opposing arguments.-Understanding the Bible requires questioning personal interpretations.-Faith involves a continuous process of learning and unlearning.-The knowledge of God is foundational to Christian beliefs.-Misinterpretations can lead to a skewed understanding of faith.-Engaging with scripture critically is essential for growth.-Personal biases can cloud one's understanding of biblical texts.-Community discussions can aid in better interpretations.-Faith is not static; it evolves with understanding.-True discernment comes from humility and openness.Chapters00:00 Discerning Truth in Faith00:06 Interpreting Biblical KnowledgeRumble Account: https://rumble.com/user/AshleyCampbellFacebook Page:https://www.facebook.com/dailyencouragementwithashleycampbell/Want to purchase a signed copy of mybook?https://buy.stripe.com/7sI8xdg6F2kZgSIfZ6ORRead the reviews on Amazon? https://a.co/d/gwyks9gWant to send me a financial donationbecause you value what I am doing on social media?https://buy.stripe.com/eVacNt3jTbVz9qg4gkWant to join my Facebook group thatwill equip you with the knowledge of the History of the United States, what the Constitution means and how you can preserve this great nation we live in?Join my paid group today! For only $10a month, you will have access to classes that will help you have the knowledge you need to save America!Group Link:https://www.facebook.com/share/RA7FqCx95Lbv5gWv/Group Payment link:https://buy.stripe.com/cN24gX07H4t70TKcMVPodcast links:Apple/I tunes:https://podcasts.apple.com/us/podcast/daily-encouragement-with-ashley-campbell/id1625607569Amazon Music:https://music.amazon.com/podcasts/4d32a7f2-1e3e-4045-aa13-2b77784c71d1/daily-encouragement-with-ashley-campbelliHeartRadiohttps://www.iheart.com/podcast/269-daily-encouragement-with-a-112334720/Overcast:https://overcast.fm/itunes1483675322/daily-encouragement-with-ashley-campbellRadio Public:https://radiopublic.com/daily-encouragement-with-ashley-c-WozzzRWant to sponsor the Podcast?https://buy.stripe.com/9AQbJpdYx8JnfOEfZ8Choose your amount to Sponsor the Podcast:https://donate.stripe.com/14k4gXg6F9Nr31SdR1

Description: Listen as NPF Medical Board Members, dermatologist Dr. Robert Kalb and rheumatologist Dr. Sergio Schwartzman discuss the connections between psoriasis and psoriatic arthritis, from cytokines to triggers, current and future treatments.   Join moderator Alan Simmons as he gains insights on what connects psoriasis and psoriatic arthritis with leading experts in psoriatic disease and NPF Medical Board members, dermatologist Dr. Robert Kalb with Buffalo Medical Group Dermatology, and rheumatologist Dr. Sergio Schwartzman from Schwartzman Rheumatology, as they discuss the known drivers of psoriasis and psoriatic arthritis, common triggers, benefits of targeted treatments, remission of disease, and upcoming treatment trends. The intent of this episode is to identify potential connections between psoriasis and psoriatic arthritis, and how targeted treatments have changed the outlook for management of psoriatic disease. This episode is sponsored by Novartis. Timestamps: (0:41) Intro to Psoriasis Uncovered and guest welcome dermatologist Dr. Robert Kalb and rheumatologist Dr. Sergio Schwartzman who are both involved in clinical care and research of psoriasis and psoriatic arthritis.  (1:15) Current known pro-inflammatory cytokines and cells found in psoriasis and psoriatic arthritis.   (5:33) Types of psoriasis that may lead to a higher risk of developing psoriatic arthritis. (9:33) Common triggers for psoriasis and psoriatic arthritis that could cause flares of the disease. (12:59) Key factors that are considered when choosing a treatment plan for any individual with psoriatic arthritis and psoriasis. (18:04) What treatment remission means for psoriasis. (19:36) Use of minimal disease activity (MDA) in psoriatic arthritis and what it means. (22:14) How a better understanding of the disease has led to more effective treatment choices and what choices are used by Dr. Kalb and Dr. Schwartzman for the management of psoriasis and psoriatic arthritis. (28:39) New developments in treatment and research in psoriatic arthritis and psoriasis. (36:01) Given treatment advancements it's a wonderful time to treat psoriatic disease. 3 Key Takeaways: ·       Cytokines are chemicals in the body that moderate various processes. In psoriasis and psoriatic arthritis,  an unknown trigger stimulates some cells to overproduce pro-inflammatory cytokines such as TNF-alpha, IL-17 or IL-23 leading to the development of skin and joint disease.  ·       Treating psoriasis and psoriatic arthritis helps move the body towards normalizing the over reactive immune system especially with more targeted treatments that safely and effectively block specific cytokines without affecting other organ systems.  ·       Given advancements in targeted treatments the goal is to reach and maintain remission of psoriatic disease. Guest Bios:   Leading dermatologist Robert Kalb, M.D. is the Chair of the Buffalo Medical Group Dermatology Department and the Director of the Buffalo Medical Group Phototherapy Center, one of the leading centers for psoriasis care in Western New York. He is also a Clinical Professor of Dermatology at the State University of New York at Buffalo School of Medicine and Biomedical Sciences (SUNY Buffalo), as well as an Adjunct Professor of Dermatology at the Perelman School of Medicine at the University of Pennsylvania where he plays a significant role in medical education, mentoring both medical students and dermatology residents. Dr. Kalb has extensive experience managing psoriasis, atopic dermatitis, and other inflammatory skin diseases. He has authored 70+ publications and is actively involved in clinical research, particularly focused on new treatment options for psoriasis. He is a member of the NPF Medical Board, American Academy of Dermatology, and is a member of the International Psoriasis Council.  Sergio Schwartzman, MD, is a world-renowned rheumatologist based in New York City who brings almost 40 years of experience and personalized clinical care for those who have psoriatic disease. Along with being in private practice at Schwartzman Rheumatology, Dr. Schwartzman is a Clinical Associate Professor of Medicine at Weill Cornell Medical College of Cornell University, the New York-Presbyterian Hospital, and the Hospital for Special Surgery in New York City where he has played a role in educating medical students, residents, fellows, and peers in rheumatology. Additionally, Dr. Schwartzman is the emeritus Franchellie M. Cadwell Clinical Associate Professor at the Hospital for Special Surgery. Dr. Schwartzman's current research interests include psoriatic arthritis, the spondyloarthritis group of diseases, ankylosing spondylitis, rheumatoid arthritis, as well as defining and treating autoimmune diseases of the eye. He has authored, co-authored, and edited over 150 papers, abstracts, books and book chapters on topics including psoriatic arthritis, ankylosing spondylitis, axial spondylarthritis, rheumatoid arthritis, lupus, autoimmune eye disorders, and other rheumatological and autoimmune conditions. He is a member of the NPF Medical Board. He is also a member of the American College of Rheumatology, the Association for Research in Vision and Ophthalmology, the Spondyloarthritis Research and Treatment Network (SPARTAN), the American Uveitis Society, and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). Resources: Ø  “Redefining Remission. A new definition for patients, providers, and payers.” Advance Online, National Psoriasis Foundation. S. Schlosser. July 14, 2025.   Ø  Treatment and Management of Psoriasis     Ø  Treatment and Management of Psoriatic Arthritis  

A meta-analysis of low-carb diets for diabetes remission found little to no effect at 12 months, clinically important harms to quality of life, and the deal-killer––an increase in LDL cholesterol.

On this episode of RNT Fitness Radio, I'm joined by long-time RNTer, Anila. Who, to be honest, is completely unrecognizable since where she started three years ago. Anila is down 30 kilos, but more than that her confidence has completely shot through the roof. Seeing her on a photo shoot day rocking outfits she probably never dreamed of and now just living life in a way that she didn't think was possible. Her type 2 diabetes has gone into remission and her health is in the best place it'sbeen. This is a really cool story and I can't wait to hear it.   Chapters: 00:00 Anila's Health Journey Begins 02:07 The Turning Point: Realizing the Need for Change 06:58 Finding the Right Program: R & T Fitness 09:45 The Initial Struggles and Learning Process 11:36 The Three-Year Transformation Journey 14:00 The Light Bulb Moment: Going All In 17:07 Support and Motivation: The Role of Pandian 19:12 Navigating the Consolidation Phase 21:07 Preparing for the Photo Shoot: Overcoming Self-Doubt 22:46 The Journey of Self-Discovery 24:08 Photo Shoot Experience and Confidence Building 26:07 Goals for Strength and Maintenance 30:18 Health Transformation and Remission 32:48 Mindset Shift and Overcoming Limitations 36:15 Impact on Motherhood and Self-Prioritization 39:11 Overcoming Fears and Setting Short-Term Goals 42:32 Final Thoughts and Encouragement   Next steps:  1) Apply for 1-1 coaching: https://www.rntfitness.co.uk/pro/   2) Take our quiz to see if you're ready for a transformation: http://www.rntfitness.co.uk/transform   3) Get our free book shipped to your door: https://bit.ly/tybtylform   4) Try our free 28 day fat loss accelerator: https://www.rntfitness.co.uk/transformation-accelerator  5) Optimum Nutrition: RNT20 for 20% off Connect with RNT Fitness:  Website  Facebook  Instagram  YouTube  Email  Connect with Akash:  Facebook  Instagram  LinkedIn 

A @Christadelphians Video: # SummaryThis presentation explores the fundamental principles of the Christian faith, particularly the doctrine of the Atonement. It delves into the biblical account of the Fall of man, the resulting sinful state of humanity, and the need for sacrifice and forgiveness as outlined in the Old Testament.Highlights

After two pregnancies—and nearly a year of feeling like she had the flu every day—Morgan (a pediatric cardiology professional and mom of two) was told “labs look normal.” Still, she had daily joint pain, low-grade fevers, shortness of breath, chest pain, dramatic weight loss, GI issues, and profound fatigue. In this raw and hopeful conversation, Dr. Isabelle Amigues shows what happens when a doctor truly listens, investigates beyond the surface, and aims for full remission—not 80%.If you've been dismissed, told to “wait it out,” or lost in the system, this episode is your proof: there is a path forward.What You'll LearnPostpartum red flags beyond “just thyroid”: when “normal labs” miss the full storyWhy low-grade daily fevers + severe fatigue should never be dismissedThe role of imaging and targeted therapy (incl. biologics) in speeding reliefHow mindset + clear plans (aiming for remission, not “good enough”) change outcomeThe difference time and listening make vs. quick, paperwork-driven visitsPractical ways to protect your energy and rebuild life after chronic symptomsWhy second (and third) opinions can be life-giving—and how to advocate for yourselfKey Topics CoveredMorgan's postpartum timeline: thyroiditis after baby #1 → much worse after baby #2The “normal labs” trap: significant symptoms with reassuring bloodworkDaily life on empty: parenting with profound fatigue, dizziness, and chest symptomsThe turning point: fevers as the objective sign that demanded deeper workupWhat felt different at UnabridgedMD: time, validation, a plan, and hopeTreatment philosophy: aim for 100%, iterate quickly if the first med isn't “the one”Mindset matters: keeping hope without denying reality (Isabelle's oncology lesson: “We're going for cure.”)Health system realities: too little time with patients, too much admin, and how listening saves time (and lives)Self-advice in hindsight: don't settle and guard your energyJoy returns: biking with kids, cooking, reconnecting—and rock climbing againGet in touch with guest Morgan: Morgan Town: Instagram @morgan.kaileyIf Morgan's story gave you hope, share this episode with a friend who's still searching for answers.Subscribe on YouTube for new episodes and practical remission-focused guidance.Have a question for Dr. Amigues? Comment on YouTube—we read every one.

The First Lady of Nutrition welcomes Lauren Vaknine, and for anyone living with rheumatoid arthritis, this is a story you won't want to miss. Diagnosed with juvenile RA just before her second birthday, Lauren was wheelchair-bound by 18 with every joint in her body locked. Most people would have lost hope—but not Lauren, and not her mother. Lauren's mom had already defied convention years earlier, saying no to steroids and choosing homeopathy instead. That decision opened the door to a lifetime of natural healing. At 21, Lauren had her own turning point: realizing her recovery was in her hands, she committed to rebuilding her health one choice at a time. Now, more than 11 years in remission, Lauren shares with Ann Louise the practices that made the difference—whole, organic foods instead of processed ones, key supplements like magnesium, cod liver oil, and black seed oil, and daily rituals with turmeric and frankincense that continue to keep her strong. From a child defined by illness to a global voice in holistic health, Lauren's message is both simple and powerful: the body knows how to heal when we give it what it needs. Learn more at laurenvaknine.co.uk The post From Rheumatoid Arthritis to Complete Remission: The Lauren Vaknine Story first appeared on Ann Louise Gittleman, PhD, CNS.

I sit down with Dr. Foran, an anesthesiologist and metabolic health practitioner who transformed her health through the carnivore diet. Dr. Foran opens up about her personal battle with ulcerative colitis and other autoimmune conditions, her experience on a vegan diet, and how embracing a carnivore lifestyle led her to not only regain her health ... Read more

On this special episode* of 'Rheumer has It', hosts Eileen and Cheryl are joined by renowned rheumatologist Dr. Loreto Carmona from Spain. The discussion centers around the concept of remission in rheumatoid arthritis (RA), highlighting the differences between medical and patient perspectives on what constitutes remission. Dr. Carmona emphasizes the importance of communication between patients and doctors, the role of medications and lifestyle factors, and the myths surrounding RA remission.This insightful conversation is part of the Canadian Talk Over RA campaign, aimed at providing hope and clear knowledge to those living with RA. See the full show notes on the Arthritis Life website for more details.Episode at a glance:00:31 Meet Dr. Loreto Carmona01:31 Defining Remission in Rheumatoid Arthritis04:26 Misconceptions About Remission07:38 Factors Influencing Remission11:30 The Importance of Communication14:48 Historical Perspectives on RA Treatment16:12 Final Thoughts and ResourcesMedical disclaimer:All content found on Arthritis Life public channels (including Rheumer Has It) was created for generalized informational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment.Episode SponsorsRheum to THRIVE, an online course and support program Cheryl created to help people with rheumatic disease go from overwhelmed, confused and alone to confident, supported and connected. See all the details and join the program or waitlist now!**Special Episode Sponsor: Talk Over RA CampaignAD - Talk Over RA is more than a campaign — it's a call to action. This podcast episode is part of the Talk Over RA 2025 campaign and is sponsored by AbbVie Canada. All content and opinions are Eileen Davidson, Cheryl Crow and Dr. Loreto's own and are not intended to promote any specific pharmaceutical products.Rheumatoid arthritis doesn't just speak through pain and fatigue — it interrupts plans, drains energy, and creates uncertainty even when symptoms are quiet. The Talk Over RA initiative encourages people living with RA to take back control by speaking up, sharing their experiences, and working with healthcare providers to set meaningful treatment goals.Eileen's role in this campaign is to provide tools that help you prepare for appointments, explore what remission could look like, and connect with others who truly understand.Don't let RA speak louder than you. Explore the campaign and download the guide here.For full episode show notesGo to the episode page on the Arthritis Life Website here. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

After experiencing stomach pains and fevers in the spring of 2023, Jordan Vanstee's then 2 year old son Kian was diagnosed with B Cell Acute Lymphoblastic Leukemia. Kian went through very difficult treatment at McMaster's Children's Hospital in Canada , but with the help of his Disney Hero Mickey Mouse and the Make a Wish Foundation, Kian is now in remission and is living his best life possible. 

What happens when someone living in and out of homelessness, battling schizophrenia, and cycling through hospitals and medications discovers ketogenic therapy?In this powerful interview, Dr. Bret Scher speaks with registered nutritional therapist Moira Newiss about one of the most remarkable published case reports to date.Despite overwhelming socioeconomic challenges, including periods of living in shelters and cooking on nothing more than a hot plate, this individual achieved sustained ketosis on a simple, affordable carnivore-based ketogenic diet.The result? His schizophrenia and psychosis went into remission.In the interview, Moira shares:The details of his journey from homelessness and hospitalization to stabilityThe simple, affordable foods he used to stay in ketosisThe barriers he faced, from relapse cycles to limited resourcesWhy this case matters for clinicians, researchers, and anyone seeking hope in the face of serious mental illnessThis case is more than a single success story, it challenges assumptions about what's possible with nutrition, even under the hardest circumstances. For someone who had been deeply embedded in psychiatric care in the UK and not improving on conventional treatment, ketogenic therapy offered a turning point.

After experiencing a persistent cough and a pain in his side, Keith Jay of Texas was encouraged to seek medical advice. Although it took a few months, in November of 2024 he was diagnosed with stage 4 lung cancer that had metastasized to his lymph glands, bones and spine. Refusing chemotherapy, a friend encouraged him to contact Corrie Yelland who told him about cannabis oil. Nine months later he is cancer free. A truly inspirational story. Visit our website: CannabisHealthRadio.comFind high-quality cannabis and CBD + get free consultations at MyFitLife.net/cannabishealthDiscover products and get expert advice from Swan ApothecaryFollow us on Facebook.Follow us on Instagram.Find us on Rumble.Keep your privacy! Buy NixT420 Odor Remover

This week on the Tom Roland podcast, I sit down with John Gluck, the author of 'An Exercise in Uncertainty.' We dive deep into discussions about fishing, life, and John's incredible journey battling Multiple Myeloma—a rare blood cancer.  Diagnosed with only 18 months to live, John has now thrived for over 21 years, thanks in part to breakthrough treatments and his passion for fishing. We also explore how fishing became a therapeutic escape for John, the power of mindset in overcoming challenges, and the role of family and career in his ongoing battle.  Tune in to hear this inspiring story and learn from John's experiences. You can also buy Jonathan's book, “An Exercise in Uncertainty” wherever books are sold.  00:00 Introduction and Greetings 00:18 Fishing in Idaho and Jackson 00:47 The Glory Days of Fishing 01:16 Challenges of the Salmon Fly Hatch 02:54 Introducing the Book: An Exercise in Uncertainty 03:17 John's Illness and Diagnosis 03:51 Fishing as a Lifeline 04:47 Writing and Fishing Adventures 08:17 Career and Writing Focus 10:23 The Diagnosis Journey 18:26 Coping with Uncertainty 26:02 Purpose and Priorities 29:10 Fishing Dreams and Realities 33:25 Reflections on Health and Life 35:42 Facing Mortality and Embracing Life 36:45 Dealing with Remission and Relapse 39:22 Finding Solace in Fishing 42:36 The Role of Diet and Exercise 44:56 Advice for Cancer Patients 48:08 Writing the Book: A Journey of Reflection 53:53 The Importance of Mindset 01:05:08 Publishing and Promoting the Book 01:13:12 Final Thoughts and Future Plans